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Abstract: Many substances of forensic interest are chiral and available either as racemates or
pure enantiomers. Application of chiral analysis in biological samples can be useful for the
determination of legal or illicit drugs consumption or interpretation of unexpected toxicological
effects. Chiral substances can also be found in environmental samples and revealed to be useful
for determination of community drug usage (sewage epidemiology), identification of illicit drug
manufacturing locations, illegal discharge of sewage and in environmental risk assessment. Thus,
the purpose of this paper is to provide an overview of the application of chiral analysis in
biological and environmental samples and their relevance in the forensic field. Most frequently
analytical methods used to quantify the enantiomers are liquid and gas chromatography using both
indirect, with enantiomerically pure derivatizing reagents, and direct methods recurring to chiral
stationary phases.
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1. Introduction
Chiral compounds are asymmetric three dimensional molecules with one or more stereogenic
centers or asymmetry originated by planes or axis that gives two non-superimposable mirror images
molecules, called enantiomers [1]. In an achiral environment, a pair of enantiomers shares similar
physical and chemical properties, however, in a chiral environment such as living organisms,
enantiomers may exhibit different biological activities and/or toxicity due to enantioselective
interactions [2–4]. Separation of enantiomers has gained relevance in forensic chemistry and has
been applied in the analysis of biological fluids, environmental samples and in the control of illicit
drug preparations [5–9]. Figure 1 summarizes the applications of chiral analysis in forensic chemistry.
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to improve sports performance or due to their psychotropic effects. The consumption of these
substances can cause toxicological effects and/or increased risk of death [10–13]. These substances
can be consumed by medical prescription or illicit practice and are available either as a racemates,
or as a single enantiomer. Data from chiral analysis in both biological samples and illicit drugs
preparations can be important in the control of manufacturing, consumption of illicit drugs or linking
between illicit drug preparations, consumers and traffickers [5,6,14]. Besides, both impurity and
chiral profile may provide a link between starting materials and the illicit drugs synthesized by
a clandestine laboratory [5,15]. Chiral analysis in biological fluids can give information regarding
consumption and differentiation between illegal drugs or legal pharmaceuticals containing only
a single enantiomer [7,16]. For example, the ingestion of dexedrine (S-(+)-amphetamine (AM)) used
in the treatment of narcolepsy, attention deficit disorders and hyperactivity in children results only
in serum concentrations of S-(+)-AM in contrast to the ingestion of the illegal AM that leads to both
enantiomers [7,8,16].
Furthermore, the presence of these compounds in wastewater has been shown to be a tool for
the monitoring drug consumption at a community level (sewage epidemiology) [17–19]. In fact,
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once excreted, residues of chiral drugs reach the aquatic environment mainly through the sewage
system as parent compounds and metabolites [20,21]. Concentration of target pharmaceuticals or
illicit drug residues in wastewater influent may be used to backcalculate drug consumption for local
communities (sewage forensics) [17,22–24]; an approach to provide direct quantitative estimates,
in a non-invasive manner and in almost real-time [17,24,25]. Since most of these compounds are chiral,
the determination of the enantiomeric fraction (EF) can give further information about the use of
legal and illegal substances. Furthermore, once in the sewage system these compounds are subject
to biotic processes that causes changes in the enantiomeric composition. This information may be
used to evaluate the efficiency of the wastewater treatment plant (WWTP) or illegal discharges of
sewage since it may be expected that their EF in untreated sewage would differ from the one observed
in treated effluents [9,18,26]. Also, information about environmental occurrence and distribution
of chiral pharmaceuticals in the environment is important for evaluation of enantio-(eco)toxicity in
particular for aquatic organisms [27–29]. In this sense, chiral analysis applied to drugs preparations,
biological fluids and environmental samples may give information about: distinction between legal
and illicit drugs; linking between samples, illegal laboratories, consumers and trafickers; estimation of
consumption patterns at community level (sewage epidemiology); identification of manufacturing
locations of illicit drugs; illegal discharge of sewage and information about ecotoxicity (Figure 1).
Concerning the importance of chiral drug analyses in various forensic contexts, the present work
aims to critical discuss the applicability of chiral drug analyses concerning pharmaceuticals and illicit
drugs in forensic chemistry regarding biological and environmental matrices. The references search
were based in ScienceDirect and ISI Web of Knowledge databases considering articles up to 2017 that
comprise biological matrices such as urine, plasma, serum, blood and hair and environmental samples
as surface waters, influents and effluents from WWTPs as aquatic environmental matrices.
2. Chromatography in Chiral Analyses
The separation of enantiomers is currently carried out using liquid chromatography (LC),
gas chromatography (GC), capillary electrophoresis (CE) and supercritical fluids chromatography [15,
20,30–44]. Chromatographic methods for resolution of enantiomers include indirect and direct methods.
The indirect method is based on the reaction of the enantiomers with chiral derivatization reagents
(CDRs) and the formation of diastereoisomers with different physico–chemical properties that can be
separated by conventional means such as chromatography. The direct method can be achieved by chiral
stationary phases (CSPs), mostly applied in LC, or using chiral mobile phase additives. Both GC and LC
methods are available in indirect and direct [35,45–49]. However, for GC only few chiral columns are
available. Thus, most works with GC used indirect approaches with CDRs, which are then separated
by achiral columns. Examples of most used CDRs are S-(−)-N-(trifluoroacetyl)propyl chloride (S-TPC),
R-(−)-α-methoxy-α-(trifluoromethyl)phenylacetyl (R-MTPCl) and S-(−)-N-(heptafluorobutyryl)propyl
chloride (S-HFBPrCl) [46,50]. Regarding direct methods, many types of CSP are available, however
the cyclodextrin (CD), Pirkle-type, polysaccharide derivatives, antibiotics-based and polymeric-based
are most used [20,51–53].
GC and LC methods have been widely used for the enantioselective analysis of various classes
of illicit drugs in biological fluids though LC methods are most used concerning environmental
samples [20,54]. This is probably due to the high number of commercial columns available for LC and
the limit of quantification that LC with mass spectrometer (MS) can be achieved. For GC methods
most work uses MS while LC use different detectors as MS, ultraviolet-visible (UV/Vis), diode array
(DAD) and fluorescence detectors (FD) (Tables 1 and 2).
LC/MS and LC/MS/MS are the most applied techniques to quantify chiral compounds in the
environment. Nevertheless, MS detection presents some limitations in the type of elution mode and
the additives that can be used. Capillary electrophoresis (CE) has also been used for the separation
of enantiomers of toxicological, doping and forensic interest due to its simplicity and inexpensive
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methodology [55]. In this work methods to quantify a variety of chiral illicit drugs and pharmaceuticals
(listed in Table 1) in biological and environmental matrices are reunited.
Table 1. Structures of the chiral illicit drugs and pharmaceuticals.
Chiral Compounds
Stimulants and their metabolites
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Table 1. Cont.
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3. Chiral Analyses in Biological Samples
This study reviewed 58 articles that have been published between 1996 and 2017 based on
ScienceDirect and ISI Web of Knowledge databases. The investigated compounds included synthetic
psychoactive drugs (stimul ts), ynthetic opioids, β-blockers, antidepressants, anticoagulants,
bronchodilators an dissociative anesthetics (Tables 1 nd 2). Figure 2 shows the relative number of
studies of each class of chiral drug investigated and th analytical methods used for analysis of these
compou ds in differe t biological matrices.
The use of racemates typic lly results in stereos l c ive ph rm co ogical activity and
pharm cokinet c aff ting bi availability, metab l sm and xcretion that may contribute to the
toxicity, increase risk of death or serious adverse effects [11,56,57]. Though there is a tendency
for manufacturing pharmaceuticals as single enantiomers, many pharmaceuticals are still supplied as
racemates [57]. Concerning illicit drugs, these compounds are also available as racemates or single
enantiomers depending on the manufacturing procedure [5,6,57]. Regarding illicit administrations,
consumption of pure enantiomer (eutomers), in some cases, may cause overdose or even might
lead to lethal cases [10,12]. Thus, significance of chiral analysis has increased since it is possible to
determine whether the drug of concern is derived from a controlled or illicit substance [58–60]. In fact,
some controlled substances are commercialized in the enantiomeric pure form due to their advantages
in therapeutic activities [5,6,57]. On the other hand, illicit production of these drugs leads to either
racemic or single e antiomers depending on the manufacturing procedure, i.e, racemic or enantiomer
pure precursors. Thus, in forensic chemistry, evaluation of the EF may aid in the discrimination of the
consumption of legal and illegal substances, give information about method of synthesis used or profile
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among different seizures linking among them, consumers and traffickers. Chiral analysis can also be
applied in doping control, as an example, the use of preparations containing dextromethorphan by
athletes is allowed, whereas the use of levorphanol is expressly banned by the International Olympic
Committee [61].
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published studies and the analytical methods used for separation of the chiral drugs in biological fluids.
Though various works have been published concerning chiral separation of the different classes of
pharmaceuticals and illicit drugs of forensic interest in biological matrices most works do not determi e
the en ntiomeric composition. Data about the enantiomeric composition of pare t compounds
and metabolites is of high imp rtance for accurate data interpretation and for further analysis f
results [62]. Also, metabolites of chiral compounds can also be chiral and should be considere in
biological samples.
3.1. Synthetic Psychoactive Drugs
This clas of chiral drug was the most studied (Tables 1 and 2 and Figure 2). Among
synthetic psychoactive drugs are the amphetamine-like drugs, a group of structurally related
compounds with vast potential for abuse, addiction and toxicity [63]. Among most studied
compounds are AM, methamphetamine (MA), 3,4-methylenedioxymethylamphetamine (MDMA),
3,4-methylenedioxy-ethylamphetamine (MDEA) and methylphenidate (MPH) (Tables 1 and 2).
Enantiomers of these drugs have been discriminated in plasma, urine, blood and hair. Analytical
methods used for the separation of enantiomers of these drugs included LC-MS, GC-FID and GC-MS
and CE. Amphetamine-like drugs can be used for the treatment of some disorders such as selegiline
(L-deprenyl, SG) used for treatment of Parkinson’s disease, Adderall or Elvanse for treatment of
attention-deficit hyperactivity disorder or famprofazone, a nonsteroidal anti-inflammatory agent,
used for pain control [8,59]. Consumption of SG produces S-MA and its metabolite S-AM while
famprofazone produces both R-MA and S-MA and their metabolites in human body [7]. Adderall
contains both R-AM and S-AM. On the other hand, these substances are often misused for recreation
purposes and even by healthy individuals to enhance work or school performance (e.g., MPH) or
doping in sport practice [64,65]. Thus, illicit preparations have been an alternative route of access these
substances by consumers and abusers. Illicit production of AM may use 1-phenyl-2-propanone and
other reagents such as formic acid, ammonium formate or formamide are used, which is designated as
the Leuckart method, yielding a racemic product [17].
Manufacture of MDMA and related drugs can use safrole, isosafrole, piperonal or
3,4-methylenedioxyphenyl-2-propanone (PMK). Many illicit drug syntheses start with PMK and
use either the Leuckart route or various reductive aminations, producing a racemic MDMA [17].
Therefore, studies based on determining the ratios of R- and S-isomers of the parent compounds
and metabolites are important for distinctive medical drug administration or illegal abuse of
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amphetamine like drugs [8]. Also, chiral information is useful and essential to identify the precursor,
the synthetic pathway, and intrinsic characteristics of the seized samples [5,6]. In this context, analysis
of the enantiomers of AM and metabolites have revealed to be very useful, since it can provide
information about the origins of the drug consumed (legal or illicit) [58,60].
In the majority of chiral amphetamine-like drugs, the S-enantiomers exhibit greater potency than
the R-enantiomers [60,66–70].
Nishida et al. described a LC-MS method for the determination of the enantiomers of MA,
AM, SG and its metabolite, desmethylselegiline (DMSG), in hair samples [59]. In this study, authors
showed differences in the enantiomer ratio of MA and AM and between MA abuse consumers and SG
consumers [59]. Besides, it was also shown that the existence of DMSG in SG users that is not normally
found in urine demonstrating that the method can be useful for distinguish therapeutic users of SG and
MA abusers. Fujii et al. described a GC-MS method based on the formation of diastereoisomers using
CDR TPC for the separation of the enantiomers of MA, AM, MDMA and MDA in urine samples [8].
This method can be used for discrimination between legal and illegal consumption of these drugs [8].
Rasmussen et al. developed for the first time a GC-MS enantioselective method for the separation
of AM, MA, MDA, MDMA and MDEA in whole blood based in the formation of diastereomers [67]
(Figure 3).
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The method was validated and applied to four whole blood samples from forensic cases including
a suspected case of driving under the influence of drugs. In all cases amphetamines were ingested as
racemates with stereoselective metabolism since the R/S ratio for most enantiomers were >1 showing
that the R-enantiomer is metabolised faster than the S-enantiomer. Hädener et al. described a two
dimensional LC-MS/MS method for quantification of AM enantiomers in human urine [16]. The study
was applied to 67 urine samples from suspected AM abusers, subjects treated with S-AM prodrug and
suspected MA abusers. In each 40 samples obtained from suspected AM abusers both enantiomers were
present and mean R/S ration was 1.25 indicating a predominance of the R-enantiomer. The excepted
value R/S would be 1 but due to stereoselective metabolism of AM in which S-AM is metabolized
faster than R-AM resulting in higher concentrations of R-AM. In the consumers of the prodrug it
was found only S-AM and R-AM in one sample at <LOQ probably due to imputities of the drug
manufacture itself [16]. Considering individuals suspected of MA consumer, in 80% of the samples,
both enantiomers were found although with a predominance of S-AM. R/S ration ranged from 0.01 to
0.47. Five samples from MA abusers contained only S-AM. This result was explained by the faster
metabolization of S-enantiomer of MA. Thus, more S-MA is converted to S-AM than R-MA to R-AM.
Binz et al. developed an analytical method for chiral analysis of AM in hair [7]. In this study,
analysis of hair samples from nine Elvanse patients revealed only S-AM in eight cases. One subject
showed both enantiomers indicating a (side-) consumption of street AM. The analysis of the 16 AM
abusers samples showed only racemic AM. Furthermore, it could be shown in a controlled study
that S-AM can be detected after administration of even very low doses of lisdexamfetamine and
dexamphetamine, which can be of interest in forensic toxicology and especially in drug-facilitated
crime [7].
MPH, another CNS stimulant, is used in the treatment of attention deficit hyperactivity disorder
(ADHD) and narcolepsy. Abuse of this substance has been reported [71]. This drug is commercialized
in the racemic mixture though only the D-threo-form is responsible for the desired therapheutic
effect. MPH is enantioselectively metabolized, preferring S-MPH over R-MPH to ritanilic acid (RA)
that is pharmacologically inactive. Individual variations on MPH metabolization classified some
individuals as poor metabolizers. Thomsen et al. developed an LC-MS/MS enantioselective method
for determination of MPH and RA in femoral blood applied to forensic cases [65] in order to evaluate
poor metabolizers by estimating R/S ratio of MPH. Postmortem blood samples from autopsy cases and
antemortem blood samples from mixture of traffic, violence and sexual assault cases were analyzed.
Apart from one case, R-MPH showed the highest concentration in the postmortem cases, a similar
pattern to the found in living organisms. Concentration of RA was higher in all cases than MPH with
equal distribution of R and S enantiomers. In antemortem individuals the same pattern was observed
with higher levels of R-MPH and equal quantities of R and S forms of RA.
These reports demonstrate that knowledge about the enantioselective behavior and measure of
the enantiomeric ratio of these types of drugs can provide useful and valuable data in the forensic
field giving information about consumption of licit and illicit amphetamine like drugs and other
psychoactive drugs and essential to aid in the correct interpretation of the use of these substances.
3.2. Synthetic Opioids
The second most studied classe of chiral compounds are the synthetic opioids (Tables 1 and 2).
Among reported compounds are tramadol, methadone and methorphan [72,73]. Opioid abuse,
addiction, and overdose are considered of a serious public health [54]. In the European Monitoring
Centre of Drug and Drug Addiction report of 2017, opioids were the third most consumed class
of drugs of abuse in Europe and the first with more fatal cases [74]. Concerning tramadol, it is a
synthetic opioid that acts as agonist by selective activity at the µ-opioid receptors commercialized
as a racemate of the more active 1R,2R-enantiomer ((+)-tramadol) and the less active 1S,2S-tramadol
((−)-tramadol), with both enantiomers acting through different mechanisms, but in a synergistic
manner [75]. However, there are differences in their binding properties leading to considerable
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differences in pharmacological activities [75]. Tramadol is metabolized to O-desmethyltramadol (ODT)
and N-desmethyltramadol (NDT). O-Demethylation of tramadol is carried out by CYP2D6; enzyme
expressed polymorphically [76]. Polymorphisms play an important role in inter-individual drug
response [77]. The metabolite ODT is pharmacologically active, has longer half-life and is more potent
than parent compounds. Tramadol has been used for nonmedical purposes due to it euphoric and
mood enhancing effects [78,79]. Tramadol abusers develop physiological dependence which can
cause negative effects such as convulsion and seizures [80]. Besides, genetic polymorphisms can
influence biological properties including toxicity. A LC-MS/MS method for separation of tramadol,
and its principal metabolites, ODT and NDT for pharmacokinetic applications in plasma samples was
reported [81]. Authors showed that plasma binding was not enantioselective, nevertheless kinetic
disposition of tramadol and its NDT metabolite was enantioselective, with plasma accumulation of
(+)-tramadol and (+)-NDT, whereas the pharmacokinetics of ODT was not enantioselective in patients
with neuropathic pain phenotyped as extensive metabolizers of CYP2D6. Thus, enantioselective
methods for both tramadol and its metabolites are essential for an accurate evaluation of their biological
properties and toxicity.
Methadone is a synthetic opioid frequently used for treatment of opiate dependent persons,
pharmacologically similar to morphine, but lacks the euphoric effects [82,83]. Methadone can be
fatal by itself or by interaction with other drugs such as depressors of the CNS. Methadone is a
substrate for CYP2B6 and CYP2C19, which are all stereoselective [83]. Plus, CYP P450 isoenzymes
are known to have individual variability (polymorphisms) that leads to poor metabolizers, rapid
metabolizers and ultra-rapid metabolizers [83]. This chiral drug, when administred as racemate gives
rise to enantiomeric metabolites S-(−)-2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and
the R-(+)-enantiomer. The R-(−)-enantiomer of methadone, is the one with higher affinity for the
µ-opioid receptor having a higher analgesic potency (over fifty times more) [82,83]. On the other
hand, the S-enantiomer is responsible for the poor cardiac tolerance [84]. In order to investigate
the enantiomeric ratios of methadone and EDDP in postmortem samples, Jantos et al. applied a
LC-MS/MS method in femoral blood, urine, bile, brain, lungs, kidneys and muscle tissue samples [82].
The study was based in sixteen samples, from eleven man and five women with ages ranging between
23 to 43 years old. Concentrations of R-methadone and R-EDDP were found in all body fluids and
tissues, while S-enantiomers were only found in thirteen of the cases. The R/S ratios ranged from
0.58 to 4.19 for methadone, and from 0.38 to 1.38 for EDDP [82]. Because methadone does not suffer
racemization in the human body, the enantiomeric ratios found in postmortem samples, can reflect if
the substance consumed was either racemic or not; also can identify if the cause of death is related to
toxic exposure [82]. Moody et al. developed an enantioselective method by LC-MS/MS for methadone
and EDDP in human plasma, urine and liver microsomes [85]. This study demonstrated differences in
the pharmacokinetic between enantiomers of methadone and its main metabolite EDDP and suggest
greater production of and lesser clearance of S-EDDP.
The antitussive dextromethorphan (allowed drug) and the narcotic analgesic levomethorphan
(banned drug, not commercially available) are the R- and R- isomers of 3-methoxy-N-methylmorphinan.
Aumatell and Wells developed a CE chiral method for separation of methorphan (racemate of
dextromethorphan and levomethorphan) [86]. Distinction of these compounds is not only of interest in
forensic science (such as the elucidation of the cause of death after intake of levomethorphan), but also
for the treatment of intoxicated patients. Also, the use of preparations containing dextromethorphan by
athletes is allowed, whereas the use of levorphanol is expressly banned by the International Olympic
Committee [61].
3.3. Antidepressants
Although antidepressants are considered non-addictive, many people abuse of these drugs [87,88].
Users can become physically dependent and non-compliance may arise as a result, with fatal
consequences in some cases [89]. Among studied antidepressants are fluoxetine (FLX), citalopram,
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reboxetine, venlafaxine (VNF) and its metabolites (Tables 1 and 2). FLX is an example of antidepressants
administrated as racemate, that both enantiomers have the same biological active. It acts by selective
inhibition of the serotonin reuptake pump, increasing the extracellular catecholamines, such as
serotonine, dopamine and norepinephrine. In the human body, it is metabolized to norfluoxetine
(NFLX). FLX enantiomers are approximately equipotent in blocking the 5-HT reuptake, while the
enantiomers of NFLX show marked differences in pharmacological activity. The enantiomer S-NFLX
shows approximately 20 times more potency than the R-enantiomer as 5-HT reuptake inhibitor, both
in vitro and in vivo [90–92]. Shen et al. considered the enantioseparation of FLX in human plasma
but its metabolite was not considered [93]. Nevertheless, Unceta et al. developed an LC-FD method
for simultaneous separation of FLX and NFLX enantiomers, in order to investigate potential sources
of variability, in rats receiving chronic treatments, on concentrations of FLX and NFLX and their
enantiomers [91]. The plasma levels of R-NFLX were considerably increased in comparison to the
S-enantiomer. In plasma FLX R/S ratios were of 1.02 compared to 1.05 in cerebral cortex, which was in
contrast with NFLX R/S ratios, that were 1.81 in plasma and 1.5 in cerebral cortex [91].
Citalopram, used in the treatment of depression, commercialized as racemate and its enantiomer
S-(+)-citalopram (escitalopram, marketed in the enantiomerically pure form) is 100 times more potent
as a serotonin reuptake inhibitor as compared to R-(−)-citalopram.
VNF is a phenylethylamine derivative that affects brain neurotransmission by blocking
presynaptic reuptake of serotonin and noradrenaline [94], and administrated in the treatment of
psychiatric disorders [95]. VNF undergoes extensive first-pass metabolism by CYP P450 enzymes
into its major active metabolite O-desmethylvenlafaxine (OD-VNF), and two minor metabolites,
N-desmethylvenlafaxine (ND-VNF) and N,O-didesmethylvenlafaxine (N,O-DD-VNF). OD-VNF
inhibits the reuptake of serotonin and noradrenaline in similar potency to that of VNF [96].
Stereoselective metabolism has been observed both in vitro and in vivo, where CYPD2D6 displays and
appreciable stereoselectivity towards the R-enantiomer [96].
Reboxetine is used as a selective noradrenaline reuptake inhibitor for the treatment of major
depressive disorders, commercialized as racemate (S,S- and R,R-reboxetine). Ohman et al. developed
an enantioseletive method for analysis of reboxetine in serum in patients with chronic medication [97].
Authors found that the median S,S/R,R ratio in steady state was 0.5 and ranged from 0.22 to 0.88.
It was also shown that women have an approximately 30% higher S,S/R,R ratio than men. The S,S/R,R
ratios of reboxetine were not found to correlate with reboxetine concentrations. Authors also found
a correlation between selective noradrenaline reuptake inhibitor activity that is higher in women than
in men and that may alter the enantiomeric ratio.
3.4. β-Blockers
β-Blockers, also known as β-adrenergic blocking agents, are a class of chiral drugs that are used
for the management of cardiac arrhythmias. Usually one enantiomer presents higher potency than the
other. For instances, S-(−)-propranolol (PHO) is 100 times more than R-(+)-PHO. Most of β-blockers
(except timolol: S-isomer) are marketed as racemates, such as acebutolol, atenolol (ATE), alprenolol,
betaxolol, carvediol, metoprolol (MET), labetalol, pindolol and sotalol [4]. In addition to therapeutic
properties, these compounds exhibit calming neurological effects decreasing anxiety, nervousness and
stabilizing motor performance. Thus, these compounds are included in prohibited list according to the
World Anti Doping Agency (WADA) regulation because of the improved psychomotor performance
that may be beneficial in sports requiring precision and accuracy such as shooting archery among
others [61]. Among β-blockers only PHO, MET, carvediol, verapamil and its metabolite enantiomers
were discriminated in plasma and urine (Tables 1 and 2) [98–101]. Analytical methods used for
the separation of enantiomers of these drugs included LC-MS and GC-MS. PHO is administered
as racemate to treat hypertension and normalize tachycardia response; however, the S-enantiomer
shows greater cardiosympatholytic activity [102]. Siluk et al. developed an analytical method for
separation of R,S-PHO in human plasma for determination of pharmacokinetic difference among
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the two enantiomers and even drugs interaction [98]. In this study, authors suggest that R-PHO
is eliminated faster than S-PHO. Concerning MET, Kim et al. developed an analytical method for
enantioseparation of its enantiomers in urine. This method can be applied in pharmacological and
pharmacokinetic studies of both enantiomers in biological samples [100]. Beyond carvediol and
verapamil, there are not studies concerning the enantioseparation of other used β-blockers in biological
samples. Methods of enantioseparation for these substances are important to evaluate pharmacological
and pharmacokinetic differences among enantiomers and possible toxicity due to interaction with
other administered drugs.
3.5. Anticoagulants
Warfarin (WFN) is one of the most commonly prescribed cardiovascular medication anticoagulant
drugs used to manage thromboembolic disease. WFN is administered as an oral medication consisting
of a racemate though the S-enantiomer has higher activity than the R-enantiomer. Several factors
increase the risk of over-anticoagulation such as genetic polymorphisms as well as others factors,
including age, sex, and histories of smoking and alcohol consumption and diets rich in vitamin
K [103]. Genetic factors and drug interactions mostly account for the risk of over-anticoagulation [103].
Knowledge about enantioselective pharmacodynamic and pharmacokinetic is not only important to
assure efficiency and safety but also because genetic polymorphisms may have an important impact in
biological properties including toxicity. Separation of WFN enantiomers was achieved using different
analytical methods: SFC-MS/MS, LC-MS/MS and Micellar electrokinetic chromatography MEKC-MS
in plasma (Tables 1 and 2) [104–106]. Knowledge about pharmacokinetic of enantiomers of WFN and
its metabolites may add in the development of enantiopure commercialized forms of WFN that may
be safer and for studies of possible toxicological and interaction of WFN with other pharmaceuticals
concomitant administered. Beyond the use of WFN as anticoagulant, this compound was used as a
poison, and is still marketed as a pesticide against rats and mices.
3.6. Dissociative Anaesthetics
Ketamine (K) began to be a widespread drug of abuse in many countries and primarily available
through illicit means. At sub anaesthetic doses this drug provides hallucinogenic effects [107,108].
Because of these desire effects K is often used in recreational purposes and particularly dangerous with
regards to traffic and workplace safety. In fact, K can be bought in the internet from suspected veterinary
distributers and clinics [109]. Chiral discrimination of K and its main metabolite norketamine (NK)
was done in in plasma and hair [110,111]. S-(+)-K is an anesthetic and analgesic but R-(−)-ketamine
is associated to hallucinations and agitation. K is a dissociative anaesthetic that induces loss of
consciousness, amnesia, immobility, and in a lesser extent analgesia [110]. It is used in paediatric
emergency retrieval and in veterinary surgery, because of its reduced tendency to give respiratory
depression [110]. Its main advantage is to induce profound analgesia and amnesia, while maintaining
the cardiopulmonary functions and the protective airway reflexes stable [110]. K undergoes extensive
first-pass metabolism to produce various free and glucurinated hydroxylated derivatives [110].
However, its main metabolic pathway occurs through N-demethylation to NK which appears to
have 20–30% activity of its parent drug [110]. Although is used as a racemate, the S-enantiomer
showed to have four times higher affinity for the phencyclidine site of the NMDA receptor, as well as
a greater potency when compare to the R-form and the racemate [110].
3.7. Bronchodilators
Among bronchodilators are β-adrenoreceptor agonists (or β2-agonists) that are drugs commonly
used for the treatment of asthma and other pulmonary disorders. They have bronchodilator and
anabolic activities. Because of these properties, these compounds may be used by athletes to enhance
performance and as a safer alternative to anabolic steroids though the use by asthmatic athletes
is not forbidden. In this sense, like β-blockers, the β-adrenergic compounds are scheduled in the
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Prohibit List of the WADA [61]. Only one report was found that describes the enantioseparation of a
bronchodilator, the salbutamol (SBT). This compound is commercialized as racemate, however the
R-enantiomer of SBT binds to β2-adrenergic receptors with greater affinity than the S-enantiomer,
which does not act through β-adrenergic receptor activation. S-SBT has adverse effects associated,
such like augmentation of bronchospasm and pro-inflammatory activities. Studies have reported
that the S-enantiomer can potentiate the effects of spasmogens in airway of smooth muscle from
both guinea pigs and humans, with a number of clinical studies also reporting worsening of airways
hyper-responsiveness in animals and in subjects with asthma [112]. The initial step in metabolism of
both enantiomers is sulfate conjugation, a stereoselective process that occurs in human airway epithelial
cells, as also in other cells and tissues [113]. The greater rate of sulfate conjugation of R-SBT might
lead to lower plasma levels of R- than S-enantiomer in human subjects, which can be responsible for
increasing the adverse effects related with the latter [112,113]. Since bronchodilator pharmacodynamic
is enantioselective the development of enantioselective methods for bronchodilators is essential for
stereo-pharmacokinetics and enantioselective safety studies. Data from pharmacokinetic studies can
contribute to the development of enantiopure broncodilators therapeutic drugs that can be safer and
used in the control of broncodilators abuse.
3.8. Anti-Helmintic
Levamisole and dexamisol [(phenyltetrahydroimidazothiazole (PTHIT)] were widely used as
an anti-worm medication for both humans and animals, but they are no longer approved for use in
the United States or Canada due to their toxicity. In South America, illicit cocaine laboratories
have been known to add PTHIT to cocaine preparations to extend their effects [10]. Casale et
al. developed an analytical method by GC-FID for the determination of PTHIT enantiomers. i.e.,
levamisole and dexamisole in illicit cocaine seizures and in urine cocaine abusers [10]. Beyond the
possibility of linking origin of cocaine seizures, the addiction of PTHIT have been shown to cause
agranulocytosis/neutropenia in cocaine abusers expanding the adverse effects of the consumption of
this drug. Approximately 78% of cocaine samples contained PTHIT in an average concentration of
23%. Enantiomeric compositions of dexamisole/levamisole were different among samples. 66% of the
samples contained levamisole, 19% the racemate and 15% the higher levels of levamisole. Samples
containing only dexamisole were not detected. The higher content in levamisole may be due to
traffickers adding tetramisole and levamisole to the cocaine or illegitimate preparation of levamisole.
Considering urine samples the majority of urine extracts contained levamisole (46%), and levamisole
enhanced enrichment (20%) and dexamisole-enhanced enrichment (26%). Levamisole has high toxicity
affecting all organ systems, with agranulocytosis, manifested primarily as acute, profound neutropenia
and have been found in concaine consumers leading to serious clinical complications. Thus, this
methodology allowed clinical toxicologists and forensic chemists to establish specific enantiomer
composition of PTHIT in cocaine samples and in the urine specimens of cocaine abusers [10]
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Table 2. Chromatographic analytical methods described for the analysis of chiral illicit drugs and pharmaceuticals in biological matrices.
Drug MatrixApplication Method Stationary Phase LOD LOQ
Concentration Range/ER
(When Mencioned) Reference
AM
Plasma GC/NICI-MS
SGE-BPX5 (15 m × 0.25 mm, 0.25 µm film thickness) 50 fg 0.049 ng/mL (R)0.195 ng/mL (S) 0.006–50 ng/mL [30]
HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) n.r. 5 µg/L
5–250 µg/L;
ER (R/S): 0.97–1.66, with a
mean value of 1.15
[114]
GC/EI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) n.r. 5 ng/g plasma 5–400 ng/g plasma [31]
Blood
GC/EI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) n.r. 0.004 µg/g 0.004–3 µg/g [67]
GC/NICI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) 0.8 pg/mg (R)0.7 pg/mg (S)
2.7 pg/mg (R)
2.4 pg/mg (S)
0.003–60 ng/mg (R)
0.002–60 ng/mg (S)
ER (R/S): 0.03–0.95
[49]
Hair
GC/EI-MS
HP5-MS (30 m × 0.25 mm, 0.25 µm film thickness) n.r. 2.5 ng/sample 2.5–100 ng/sample [31]
5% phenyl-methylsilicone capillary column (17 m × 0.2
mm, 0.33 µm film thickness) 0.1 ng/mg 0.2 ng/mg 0.2–20 ng/mg [69]
LC/MS/MS n.r. 20 pg/mg 50 pg/mg 50–20000 pg/mg [7]
HPLC/ESI-MS Chiral DRUG (150 mm × 2 mm) 0.05 ng/mg n.r. 0.2–40 ng/mg [59]
Urine
GC/EI-MS
DB-5MS (20 m × 0.18 mm × 0.18 mm) 10 ng/mL n.r. 25–10000 ng/mL [115]
HP-5MS (20 m × 0.25 mm, 0.25 µm film thickness) n.r. 10 µg/L 10–500 µg/L [42]
HP-5MS (30 m × 0.2 mm, 0.33 µm film thickness) 40 ng/mL 45 ng/mL 45–1000 (l; d)45–2000 (d,l) [70]
5% phenyl polysiloxane (15 m × 0.2 mm, 0.2 µm df) n.r. n.r. 25–10000 ng/mL [116]
GC/MS
HP-5MS (20 m × 0.25 mm, 0.25 µm film thickness) 1.1 ng/mL (R)1.3 ng/mL (S)
3.7 ng/mL (R)
4.3 ng/mL (S) 5–500 µg/L [117]
DB-5 (10 m × 0.1 mm, 0.4 µm film thickness) 0.5 ng/mL n.r. 20–1000 ng/mL [8]
CE/ESI-MS Uncoated fused silica capillary (50 µm, 100 cm)
0.02 µg/mL n.r. 0.05–10 µg/mL [33]
0.03 µg/mL n.r. 0.2–10 µg/mL (S) [118]
CE PVA chemically modified diol capillary column(40 cm × 50 µm) n.r. n.r. n.r. [36]
LC/MS-MS
Lux AMP (150 × 3 mm, 5 µm) n.r. 0.05 mg/L 0.05–25 mg/L [16]
Chirobiotic V2 (250 × 2.1 mm, 5 µm) 0.02 mg/L 0.05 mg/L 0.05–50.00 mg/L [60]
HPLC-UV Adsorbosphere HS, C18 (150 × 4.6 mm, 5µm); C18precolumn (7.5 × 4.6 mm) n.r. n.r. 0.1–100 mg/L [119]
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Table 2. Cont.
Drug MatrixApplication Method Stationary Phase LOD LOQ
Concentration Range/ER
(When Mencioned) Reference
MA
Plasma GC/NICI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) n.r. 5 µg/L
5–250 µg/L
ER (R/S): 1.02–1.63, with a
mean value of 1.33
[114]
Blood GC/EI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) n.r. 0.004 µg/g 0.004–3 µg/g [67]
Hair
GC/NICI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) 2.1 pg/mg (R)1.5 pg/mg (S)
6.9 pg/mg (R)
5.0 pg/mg (S)
0.007–60 ng/mg (R)
0.005–60 ng/mg (S)
ER (R/S): 0.01–0.82
[49]
GC/MS 5% phenyl-methylsilicone capillary column (17 m × 0.2mm i.d., 0.33 µm film thickness) 0.1 ng/mg 0.2 ng/mg 0.2–20 ng/mg [69]
HPLC/ESI-MS Chiral DRUG (150 mm × 2 mm) 0.01 ng/mg n.r. 0.04–40 ng/mg [59]
Urine
GC/EI-MS
DB-5MS (20 m × 0.18 mm i.d. × 0.18 mm) 10 ng/mL n.r. 25–10000 ng/mL [115]
HP-5MS (30 m × 0.2 mm, 0.33 µm film thickness) 40 ng/mL 45 ng/mL 45–1000 (l; d)45–2000 (d,l) [70]
HP-5MS (20 m × 0.25 mm, 0.25 µm film thickness) n.r. 10 µg/L 10–500 µg/L [42]
5% phenyl polysiloxane (15 m × 0.25 mm, 0.2 µm df) n.r. n.r. 25–10000 ng/mL [116]
GC/MS
HP-1 (12 m × 0.25 mm, 0.25 µm film thickness) n.r. 10 ng/mL 10–2000 ng/mL [120]
HP-5MS (20 m × 0.25 mm, 0.25 µm film thickness) 2.0 ng/mL (R)1.6 ng/mL (S)
6.8 ng/mL (R)
5.2 ng/mL (S) 5–500 µg/L [117]
DB-5 (10 m × 0.1 mm, 0.4 µm film thickness) 3 ng/mL n.r. 20–1000 ng/mL [8]
CE/ESI-MS Uncoated fused silica capillary (50 µm, 100 cm)
0.02 µg/mL n.r. 0.05–10 µg/mL [33]
0.03 µg/mL n.r. 0.2–10 µg/mL (S) [118]
CE PVA chemically modified diol capillary column (40 cm× 50 µm) n.r. n.r. n.r. [36]
LC/MS/MS Chirobiotic V2 (250 × 2.1 mm, 5 µm) 0.02 mg/L 0.05 mg/L 0.05–50.00 mg/L [60]
HPLC-UV Adsorbosphere HS, C18 (150 × 4.6 mm, 5µm); C18precolumn (7.5 × 4.6 mm) n.r. n.r. 0.1–100 mg/L [119]
MDMA
Plasma HPLC-DAD ODS-1 (150 mm × 4.6 mm) with precolumn (20 × 4.0mm) n.r. 7 ng/mL n.r. [121]
Blood
GC/EI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) n.r. 0.004 µg/g 0.004–3 µg/g [67]
LC/MS/MS Kinetex C18 column (100 × 2.1 mm, 2.6 µm filmthickness) n.r. 0.0025 µg/L 0.0025–1.25 µg/L (R, S) [122]
Hair GC/NICI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) 1.7 pg/mg (R)1.5 pg/mg (S)
5.6 pg/mg (R)
5.1 pg/mg (S)
0.006–60 ng/mg (R)
0.005–60 ng/mg (S) [49]
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Table 2. Cont.
Drug MatrixApplication Method Stationary Phase LOD LOQ
Concentration Range/ER
(When Mencioned) Reference
GC/MS 5% phenyl-methylsilicone capillary column (17 m × 0.2mm, 0.33 µm film thickness) 0.2 ng/mg 0.5 ng/mg 0.5–20 ng/mg [69]
Urine
GC/NICI-MS
LC/HRMS
n.r. (chiral derivatization S-HFBPrCl)
Chirex3012 (250 × 4.6 mm, 5 µm film thickness) n.r. n.r. n.r. [68]
GC/EI-MS
HP-5MS (20 m × 0.25 mm, 0.25 µm film thickness) n.r. 10 µg/L 10–500 µg/L [42]
5% phenyl polysiloxane (15 m × 0.25 mm, 0.2 µm df) n.r. n.r. 25–10000 ng/mL [116]
GC/MS HP-5MS (20 m × 0.25 mm, 0.25 µm film thickness) 1.7 ng/mL 5.7–5.8 ng/mL 5–500 µg/L [117]
HPLC-DAD ODS-1 (150 × 4.6 mm) with precolumn (20 × 4.0 mm) n.r. 7 ng/mL n.r. [121]
MDA
Plasma HPLC-DAD ODS-1 (150 × 4.6 mm) with precolumn (20 × 4.0 mm) n.r. 5 ng/mL n.r. [121]
Blood LC/MS/MS Kinetex C18 column (100 × 2.1 mm, 2.6 µm filmthickness) n.r. 0.0025 µg/L 0.0025–0.25 µg/L (R, S) [122]
Hair
GC/NICI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) 1.6 pg/mg (R)1.3 pg/mg (S)
5.3 pg/mg (R)
4.3 pg/mg (S)
0.005–60 ng/mg (R)
0.004–60 ng/mg (S) [49]
GC/MS 5% phenyl-methylsilicone capillary column (17 m × 0.2mm, 0.33 µm film thickness) 0.1 ng/mg 0.2 ng/mg 0.2–20 ng/mg [69]
Urine
GC/NICI-MS
LC/HRMS
n.r. (chiral derivatization S-HFBPrCl)
Chirex3012 (250 × 4.6 mm, 5 µm film thickness) n.r. n.r. n.r. [68]
GC/EI-MS
HP-5MS (20 m × 0.25 mm, 0.25 µm film thickness) n.r. 2 µg/L 2–100 µg/L [42]
5% phenyl polysiloxane (15 m × 0.25 mm, 0.2 µm df) n.r. n.r. 25–10000 ng/mL [116]
HPLC-DAD ODS-1 (150 × 4.6 mm) with precolumn (20 × 4.0 mm) n.r. 5 ng/mL n.r. [121]
MDEA
Whole blood GC/EI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) n.r. 0.004 µg/g 0.004–3 µg/g [67]
Hair
GC/NICI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) 2.7 pg/mg (R)2.3 pg/mg (S)
8.9 pg/mg (R)
7.7 pg/mg (S)
0.009–60 ng/mg (R)
0.008–60 ng/mg (S) [49]
GC/MS 5% phenyl-methylsilicone capillary column (17 m × 0.2mm i.d., 0.33 µm film thickness) 0.2 ng/mg 0.5 ng/mg 0.5–20 ng/mg [69]
Urine GC/EI-MS 5% phenyl polysiloxane (15 m × 0.25 mm, 0.2 µm df) n.r. n.r. 25–5000 ng/mL [116]
pOHMA
Blood LC/MS/MS Kinetex C18 column (100 × 2.1 mm, 2.6 µm filmthickness) n.r. 0.0025 µg/L 0.0025–0.25 µg/L (R, S) [122]
Urine
GC/NICI-MS
LC/HRMS
n.r. (chiral derivatization S-HFBPrCl)
Chirex3012 (250 × 4.6 mm, 5 µm film thickness) n.r. n.r. n.r. [68]
CE/ESI-MS Uncoated fused silica capillary (50 µm, 100 cm)
0.02 µg/mL n.r. 0.05–10 µg/mL [33]
0.05 µg/mL n.r. 0.2–10 µg/mL (S) [118]
CE PVA chemically modified diol capillary column (40 cm× 50 µm) n.r. n.r. n.r. [36]
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Table 2. Cont.
Drug MatrixApplication Method Stationary Phase LOD LOQ
Concentration Range/ER
(When Mencioned) Reference
HMMA Blood LC/MS/MS Kinetex C18 column (100 × 2.1 mm, 2.6 µm film thickness) n.r. 0.0025 µg/L 0.0025–0.25 µg/L (R, S) [122]
Methadone
Plasma
LC/EI-MS/MS Chiral-AGP (50 × 2.0 mm, 5 µm) n.r. 2.5 ng/mL 0–500 ng/mL [85]
LC/MS Chiral-AGP (100 × 4.0 mm, 5 µm); Chiral-AGP guardcolumn (10 × 2.0 mm, 5 µm) 0.02 ng/mL 1 ng/mL 1–300 ng/mL [83]
Blood
LC/ESI-MS/MS Chiral-AGP (100 × 4.0 mm, 5 µm); Chiral-AGP guardcolumn (10 × 2.0 mm, 5 µm) n.r. n.r. n.r. [12]
LC/MS α-1-acid glycoprotein (100 × 4.0 mm, 5 µm) and a α-1-acidglycoprotein guard column (10 × 2.0 mm, 5 µm) n.r. 0.02 mg/L 0.05–2.1 mg/L [123]
Blood
Tissues LC/MS/MS Chiral-AGP column (150 × 3 mm, 5 µm)
0.65 ng/L (R)
0.49 ng/L (S)
2.40 ng/L (R)
1.82 ng/L (S) 50–1000 ng/L [82]
Urine LC/EI-MS/MS Chiral-AGP (50 × 2.0 mm, 5 µm) n.r. 2.5 ng/mL 0–500 ng/mLER (R/S): 1.42–2.96 [85]
Liver LC/EI-MS/MS Chiral-AGP (50 × 2.0 mm, 5 µm) n.r. 2.5 ng/mL 0–500 ng/mL [85]
EDDP
Plasma
LC/MS Chiral-AGP (100 × 4.0 mm, 5 µm); Chiral-AGP guardcolumn (10 × 2.0 mm, 5 µm) 0.01 ng/mL 0.1 ng/mL 1–25 ng/mL [83]
LC/EI-MS/MS Chiral-AGP (50 × 2.0 mm, 5 µm) n.r. 2.5 ng/mL 0–500 ng/mL [85]
Blood LC/ESI-MS/MS Chiral-AGP (100 × 4.0 mm, 5 µm); Chiral-AGP guardcolumn (10 × 2.0 mm, 5 µm) n.r. n.r. n.r. [12]
Blood
Tissues LC/MS/MS Chiral-AGP column (150 × 3 mm, 5 µm)
0.77 ng/L (R)
0.76 ng/L (S)
2.82 ng/L (R)
2.79 ng/L (S) 50–1000 ng/L [82]
Urine LC/EI-MS/MS Chiral-AGP (50 × 2.0 mm, 5 µm) n.r. 2.5 ng/mL 0–500 ng/mLER (R/S): 0.76–0.89 [85]
Liver LC/EI-MS/MS Chiral-AGP (50 × 2.0 mm, 5 µm) n.r. 2.5 ng/mL 0–500 ng/mL [85]
T
Plasma
LC/ESI-MS/MS Chiralpak AD (250 × 4.6 mm, 10 µm) n.r. 0.2 ng/mL (total)0.5 ng/mL (unbound)
0.2–600 ng/mL (total)
0.5–250 ng/mL (unbound) [81]
LC/APCI-MS/MS
Lux Cellulose-2 (150 × 4.6 mm, 3 µm); Lux Cellulose-2
guard column (4 × 3 mm) 0.15 ng/mL 1 ng/mL 1–800 ng/mL [75]
Chiralpak AD (250 × 4.6 mm, 10 µm) 1 ng/mL 3 ng/mL 25–1000 ng/mL [34]
HPLC-DAD Chiralcel OD-R (250 × 4.6 mm, 10 µm); LiChrospher60-RP-selected B (250 × 4 mm, 5 µm)
0.18 ng/mL (+)
0.16 ng/mL (-) 1 ng/mL 1–500 ng/mL [124]
HPLC-FD
Chiralpak AD (250 × 4.6 mm, 10 µm) 1 nM 5 nM 0.01–1.55 µM [125]
Chiralpak AD (250 × 4.6 mm); LichroCART 4-4
LiChrospher 100 Diol (5 µm) precolumn n.r. 2.5 ng/mL 2.5–250 ng/mL [126]
Chiral-AGP (150 × 4.0 mm, 5 µm); Chiral-AGP guard
column (10 × 4.0 mm, 5 µm) n.r. 2 ng/mL 2–200 ng/mL [127]
Urine
GC/EI-MS Rt-βDEXcst (30m × 0.25 mm, 0.25 µm film thickness) 0.01 µg/mL 0.1 µg/mL 0.1–20 µg/mL [128]
HPLC-FD Chiralpak AD (250 × 4.6 mm, 10 µm) 2 nM 25 nM 0.1–3.0 µM [125]
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Table 2. Cont.
Drug MatrixApplication Method Stationary Phase LOD LOQ
Concentration Range/ER
(When Mencioned) Reference
ODT
Plasma
LC/ESI-MS/MS Chiralpak AD (250 × 4.6 mm, 10 µm) n.r. 0.1 ng/mL (total)0.25 ng/mL (unbound)
0.1–300 ng/mL (total)
0.25–125 ng/mL (unbound) [81]
LC/APCI-MS/MS
Lux Cellulose-2 (150 × 4.6 mm, 3 µm); Lux Cellulose-2 guard
column (4 × 3 mm)
0.20 ng/mL (+)
0.30 ng/mL (-) 1 ng/mL 1–400 ng/mL [75]
Chiralpak AD (250 × 4.6 mm, 10 µm) 1.3 ng/mL 4 ng/mL 25–1000 ng/mL [34]
HPLC-DAD Chiralcel OD-R (250 × 4.6 mm, 10 µm); LiChrospher60-RP-selected B (250 × 4 mm, 5 µm)
0.08 ng/mL (+)
0.06 ng/mL (-) 0.5 ng/mL 0.5–100 ng/mL [124]
HPLC-FD
Chiralpak AD (250 × 4.6 mm, 10 µm) 1 nM 5 nM 0.01–1.55 µM [125]
Chiralpak AD (250 × 4.6 mm); LichroCART 4-4 LiChrospher
100 Diol (5 µm) precolumn n.r. 2.5 ng/mL 2.5–250 ng/mL [126]
Chiral-AGP (150 × 4.0 mm × 5 µm); Chiral-AGP guard
column (10 × 4.0 mm × 5 µm) n.r. 2.5 ng/mL 2.5–100 ng/mL [127]
Urine
GC/EI-MS Rt-βDEXcst (30 m × 0.25 mm, 0.25 µm film thickness) 0.03 µg/mL 0.1 µg/mL 0.1–20 µg/mL [128]
HPLC-FD Chiralpak AD (250 × 4.6 mm, 10 µm) 2 nM 25 nM 0.1–3.0 µM [125]
NDT Plasma
LC/ESI-MS/MS Chiralpak AD (250 × 4.6 mm, 10 µm) n.r. 0.1 ng/mL (total)0.25 ng/mL (unbound)
0.1–300 ng/mL (total)
0.25–125 ng/mL (unbound) [81]
HPLC-DAD Chiralcel OD-R (250 × 4.6 mm, 10 µm); LiChrospher60-RP-selected B (250 × 4 mm, 5 µm)
0.15 ng/mL (+)
0.16 ng/mL (-) 0.5 ng/mL 0.5–250 ng/mL [124]
HPLC-FD Chiral-AGP (150 × 4.0 mm, 5 µm); Chiral-AGP guard column(10 × 4.0 mm, 5 µm) n.r. 2.5 ng/mL 2.5–75 ng/mL [127]
N,O-DDM-T Plasma HPLC-FD Chiralpak AD (250 × 4.6 mm); LichroCART 4-4 LiChrospher100 Diol (5 µm) precolumn n.r. 2.5 ng/mL 2.5–250 ng/mL [126]
Citalopram Plasma LC/ESI-MS/MS Chiralcel OD-R (250 × 4.6 mm × 10 µm); LiChrospher 100RP-8 precolumn (4 × 4.0 mm × 5 µm) n.r. 0.1 ng/mL 0.1–20 ng/mL [129]
FLX Plasma LC/APCI-MS/MS Chirobiotic V (250 × 4.6 mm, 5 µm) n.r. 2 ng/mL 2–1000 ng/mL [93]
K
Plasma LC/MS Chiral-AGP (100 × 4.0 mm, 5 µm); Chiral-AGP guard column(10 × 2.0 mm, 5 µm) 0.25 ng/mL 1 ng/mL 1–125 ng/mL [111]
Hair CE-UV-DAD Uncoated fused-silica capillary (450 × 50 mm) 0.08 ng/mg 0.25 ng/mg 0.5–8.0 ng/mg [110]
NK Plasma LC/MS Chiral-AGP (100 × 4.0 mm, 5 µm); Chiral-AGP guard column(10 × 2.0 mm, 5 µm) 0.25 ng/mL 1 ng/mL 1–125 ng/mL [111]
Hair CE-UV-DAD Uncoated fused-silica capillary (450 × 50 mm) 0.08 ng/mg 0.25 ng/mg 0.5–8.0 ng/mg [110]
MPH
Plasma GC/NICI-MS BPX5 fused silica (15 m × 0.25 mm) n.r. 0.006 ng/mL 0.006–12.5 ng/mL [130]
n.r. 0.072 ng/mL 0.072–18.25 ng/mL [131]
Blood LC/MS/MS Chiral AGP (100 × 4.0 mm, 5 µm); guard column (10 × 2.0mm, 5 µm) n.r. n.r. 0.2–500 ng/g [65]
Urine GC/EI-MS DB-5 (30 m × 0.32 mm, 0.25 µm film thickness) n.r. 10 ng/mL 0–10000 ng/mL [132]
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Table 2. Cont.
Drug MatrixApplication Method Stationary Phase LOD LOQ
Concentration Range/ER
(When Mencioned) Reference
Reboxetine Serum LC/MS Chiral-AGP (2 × 100 mm, 5 µm) <1 nmol/L n.r.
50–500 nmol/L
ER (S/R): 0.22–0.88, with a
mean value of 0.5
[97]
VNF
Plasma
LC/ESI-MS/MS Chirobiotic V (250 × 2.1 mm, 5 µm) n.r. 0.5 nM 1–1000 nMER (S/R): 1.01–4.33 [95]
HPLC/ESI-MS Chirobiotic V (250 × 4.6 mm, 5 µm) 1 ng/mL 5.2 ng/mL (R)5 ng/mL (S) 5–400 ng/mL [133]
Whole blood LC/ESI-MS/MS Chirobiotic V (250 × 2.1 mm, 5 µm) n.r. 0.5 nM 10–4000 nMER (S/R): 0.59–1.11 [95]
OD-VNF
Plasma
LC/ESI-MS/MS Chirobiotic V (250 × 2.1 mm, 5 µm) n.r. 0.5 nM 1–1000 nMER (S/R): 0.70–12.3 [95]
HPLC/ESI-MS Chirobiotic V (250 × 4.6 mm, 5 µm) 1.5 ng/mL 3.5 ng/mL (R)4.3 ng/mL (S) 4–280 ng/mL [133]
Whole blood LC/ESI-MS/MS Chirobiotic V (250 × 2.1 mm, 5 µm) n.r. 0.5 nM 10–4000 nMER (S/R): 0.59–1.11 [95]
ND-VNF Plasma LC/ESI-MS/MS Chirobiotic V (250 × 2.1 mm, 5 µm) n.r. 0.25 nM
0.5–500 nM
ER (S/R): 1.24–2.91 [95]
Whole blood LC/ESI-MS/MS Chirobiotic V (250 × 2.1 mm, 5 µm) n.r. 0.25 nM 5–2000 nMER (S/R): 0.46–1.53 [95]
N,O-DD-VNF
Plasma LC/ESI-MS/MS Chirobiotic V (250 × 2.1 mm, 5 µm) n.r. 0.25 nM 0.5–500 nMER (S/R): 0.42–1.18 [95]
Whole blood LC/ESI-MS/MS Chirobiotic V (250 × 2.1 mm, 5 µm) n.r. 0.25 nM 5–2000 nMER (S/R): 0.90–1.99 [95]
MET Urine GC/EI-MS HP-5MS (30 m × 0.25 mm, 0.25 µm film thickness) 0.5 ng/mL n.r. 0.1–4 ng/mLER (R/S): 0.83 [100]
PHO Plasma LC/APCI-MS Chirobiotic V (250 × 4.6 mm, 5 µm); Chirobiotic Vguard column (20 × 4.0 mm, 5 µm) 0.03 ng/mL 0.25 ng/mL 0.25–200 ng/mL [98]
WFN Plasma
SFC/APCI-MS/MS Chiralpak AD (250 × 4.6 mm); Chiralpak AD-H guardcolumn (10 × 4.0 mm) n.r. 13.6 ng/mL 13.6–2500 ng/mL [104]
LC/ESI-MS/MS Chirobiotic V (250 × 4.6 mm, 5 µm); Cyclobond I guardcolumn (20 × 4.0 mm, 5 µm) 1.5 ng/mL 5 ng/mL
5–1500 ng/mL
ER (S/R): 0.47±0.14 [105]
MEKC/ESI-MS Fused silica capillaries (120 cm, 375 µm o.d., 50 µm) 0.1 µg/mL (instr.limit) n.r.
0.25–5 µg/mL
ER (R/S): 2.24–6.20 [106]
Carvedilol Plasma LC/ESI-MS/MS
Chirobiotic T (250 × 4.6 mm, 10 µm) n.r. 0.2 ng/mL 0.2–500 ng/mL [99]
Ace 3 C18 (50 × 2.0 mm, 3 µm) n.r. 0.2 ng/mL 0.2–200 ng/mL [134]
Verapamil Plasma CE-UV Fused-silica capillaries n.r. n.r. 2.5–250 ng/mL [101]
Molecules 2018, 23, 262 22 of 47
Table 2. Cont.
Drug MatrixApplication Method Stationary Phase LOD LOQ
Concentration Range/ER
(When Mencioned) Reference
Norverapamil Plasma CE-UV Fused-silica capillaries n.r. n.r. 2.5–250 ng/mL [101]
SBT Urine NACE/ESI-MS Fused silica capillaries (48.5 cm, 375 µm o.d., 50 µm) 8–14 ng/mL 18–20 ng/mL 15–150 ng/mL [135]
PTHIT Urine GC-FID Rt-β-DEXsm (30 m × 0.25 mm, 0.25 µm film thickness n.r. n.r. n.r. [10]
AM: amphetamine; CE: capillary electrophoresis; CI: chemical ionization; DAD: diode array detection; EDDP: 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine; EI: electron
impact; ER: enantiomeric ratio; ESI: electrospray ionization; FD: fluorescence detector; FID: flame ionization detector; FLX: fluoxetin; GC: gas chromatography; HMMA:
4-hydroxy-3-methoxymethamphetamine; HPLC: high performance liquid chromatography; K: ketamine; LC: liquid chromatography; LOD: limit of detection; LOQ: limit of quantification;
MA: methamphetamine; MDA: 3,4-Methylenedioxyamphetamine; MDMA: 3,4 Methylenedioxymethamphetamine; MDEA: N-methyl-diethanolamine; MEKC: micellar electrokinetic
chromatography; MET: metoprolol; MPH: methylphenidate; MS: mass spectrometry; MS/MS: tandem mass spectrometry; NACE: nonaqueous capillary electrophoresis; NDT:
N-desmetil-tramadol; ND-VNF: N-desmethylvenlafaxine; NICI: negative ion chemical ionization; N,O-DD-VNF: N,O-didesmethylvenlafaxine; NFLX: norfluoxetin; NK: norketamine;
ODT: O-desmetil-tramadol; OD-VNF: O-desmetil-venlafaxine; PHO: propranolol; PTHIT: phenyltetrahydroimidazothiazole; SBT: salbutamol; T: tramadol; UV: ultraviolet detector; VNF:
venlafaxine; WFN: warfarin. n.r.: not referred.
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4. Chiral Analyses in the Aquatic Environment
This study reviewed 33 articles that have been published between 2005 and 2017 based in
ScienceDirect and ISI web of Knowledge databases (Table 3 and Figure 4). The target compounds
included antidepressants, β-blockers, nonsteroidal anti-inflamatory drugs (NSAIDs), synthetic
psychoactive drugs, antibiotics, synthetic opioids, antiepileptics, antihistaminic; bronchodilators,
antineoplastic agents and proton pump inhibitors (Table 1). Figure 4 shows the relative number of
studies of each class of chiral drug investigated and the analytical methods used for analysis of these
compounds in different environmental matrices.
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The entrance of pharmaceuticals and illicit drugs into aquatic environment may occur th ough
effluents from WWTPs which re u able to to ally r move these micro-pollutants or direct discharged
of sewage. WWTPs biological tr atm nts, can alter the EF of the enantiomers present in the influent,
as micr biota action gener lly is ster oselective [136,137]. Disposed drugs will usually be found in
their parent form, either as racemate or single enantio ers. On the other hand, excreted drugs will be
normally found as metabolites, frequently chiral, of the parent compound [138].
The possible adverse effects of the enantiomers on aquatic and human life lead to the studies
of occurrence of chiral drugs in environmental matrices [20,136,137,139,140]. Illicit drugs can also
be found in environmental samples, and environmental data are important resources for a forensic
approach. This includes the usage of environmental data in order to: (1) verify patterns of illicit and
prescribed drugs usage in local communities (2) application of drugs as chemical markers of faecal
water contamination with (human) sewage and (3) verify the source of drugs (legal or illicit) [20,136,
137,139,140].
The estimation of the consumption of substances of abuse and illicit drugs can be measured by
the concentrations of these compounds in wastewater. Drugs are consumed and metabolised in human
body and excreted as parent compounds or as metabolites, and finally reach WWTPs through the
sewage [139]. Since the metabolic patterns of most available drugs are understood, it is assumed that
t e amount of drug or its metabolite qua tified in raw sewage will c rrespond with the consumed
dose—sewage epidemiology [139]. The application of th chiral discrimination has also been used for
distinction between legal and illicit use of drugs, verification of the method of synthesis of illicit drugs,
identification that drug residue results either from consumption of illicit drugs or metabolism of other
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drugs, verification of route of administration, verification of potency of abused drugs, monitoring of
changing patterns of drugs abused, and differentiation between consumption and disposal of unused
drugs [17,141].
Concerning biodegradation, ecotoxicity and environmental fate, the recognition of
enantioselectivity is essential to provide a more realistic risk assessment of chiral compounds.
The fate of chiral drugs in the environment can be studied by monitoring their EF during biological
processes [20,38,136]. Degradation of these compounds relies on both abiotic and biotic processes [142].
Biodegradation in WWTP is expected to be stereoselective, which changes the EF of a given molecule
in the sample, consequently bringing different removals/degradation rates [142]. Over the past five
years, the amount of research published in chiral environmental analysis has been increasing on a
high rate. Knowledge on how chiral micropollutant, such as pharmaceuticals and illicit drugs, behave
in the environment, especially in water samples, either wastewater or superficial water, has been
providing valuable information, both for risk assessment and WWTPs efficiency [139,142]. The EF of
certain pharmaceuticals, such as PHO, alprenolol, VNF and climbazole [136,143,144] in surface waters,
can reveal the efficiency of different WWTPs [136,139,140,143–146]. Additional these compounds
have been pointed as indicators to differentiate between treated and untreated water. Analysis of
wastewater samples are mostly done by comparing the EF of the influent and effluent of the target
analytes, which gives an overview of the efficiency and of the WWTPs [9,147,148].
According to Kasprzyk-Hordern et al., since WWTPs are fed by fresh sewage, a long-term
monitoring programme of drugs might reveal their usage patterns in local communities and their
changes over longer periods of time [139]. This is the main route that chiral drugs enter the
environment, and these can be found either in a modified form (metabolites) and/or with alterations in
their enantiomeric EF due to human metabolism [138]. In the first attempt to apply chirality to sewage
epidemiology, Kasprzyk-Hordern et al., collected wastewater samples over a period of 8 months,
from seven WWTPs in London, during five sampling campaigns and, quantified the levels of AM, MA,
MDMA, MDA, ephedrine and pseudoephedrine enantiomers [149]. The samples were enriched with
R-AM, S-MA, S-MDA, 1R,2S-(−)-ephedrine and 1S,2S-(+)-pseudoephedrine. However, the authors
could not reach any conclusion according to the use of illicit drugs, since AM and MA enantiomers can
also result from the metabolism of chiral pharmaceuticals. On the other hand, when comes to MDMA
and MDA, the enantiomeric profiling proved to be invaluable in making distinction between MDA
abuse and its formation due to metabolism of MDMA, suggesting that this profiling could also help
with making a distinction between actual consumption and direct disposal [17].
Vasquez-Roig et al., in a two week study of three WWTPs located in the city of Valencia (Spain)
and surroundings, described the enantiomeric profile of some chiral drugs [148]. Although for
some of the target analytes it was not possible to study their enantiomeric fate, since these were
present in very low concentrations, which was the case of MDMA and AM, they were able to
observe enantiomeric enrichment ofATE, where the S-enantiomer was in higher abundance in raw
wastewater, meanwhile during the wastewater treatment, enrichment of both R- or S-enantiomer were
observed [148]. This difference in enantiomeric enrichment seemed to be related with the technology
used by the treatment plant. Although all of three used activated sludge, one of the plants had
also biological nitrogen removal, which the authors believe that different bacteria were involved
in this process (in aerobic conditions), that could favour the degradation of R-ATE, leading to an
enrichment of S-ATE [148]. They also found enrichment at similar levels of 1R,2S-(−)-ephedrine and
1S,2S-(+)-pseudoephedrine in raw wastewater. In terms of elimination rates these ranged from 29 to
100% and showed to be compound and enantiomer dependent. AM and MA were not detected in
effluents, however stereoselective degradation was observed for MDMA, where the S-enantiomer was
more readily degraded than the R-MDMA. Atenolol was found to be poorly removed, thus S-atenolol
removal efficiency was higher than R-atenolol [148]. VNF concentrations increased in two of the
WWTPs after sewage treatment, which in according to the authors, was due to biotic effects, such like,
elimination of glucuronide metabolites, back-reversion of the demethylated metabolite, or desorption
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from particulate matter [148]. The application of wastewater enantiomeric profiling revealed usage
patterns of chiral drugs in the region, where the consumption of AM showed an irregular pattern
throughout the two-week sampling campaign, while MA showed a slight increase in daily loads,
throughout the weekend in one of the WWTPs. MDMA showed a clear weekly pattern of increased
daily loads, during weekends [148].
Hashim, N. H. & Khan, S. J. studied the EFof ibuprofen, naproxen and ketoprofen in wastewater
samples, taken from a WWTPs in Sydney (Australia) with tertiary treatment over seven separate
sampling events, during June and August 2010 [147]. For ibuprofen, EF ranged from 0.49 and
0.62; 0.66 and 0.86 for naproxen and 0.54 and 0.66 for ketoprofen [147]. Also Barreiro et al in 2010,
found for the first time the occurrence of (+)-omeprazole and (−)-omeprazole, while simultaneously
developing a column switching, liquid chromatography method for the chiral separation of these
drugs, in wastewater and estuarine samples [150]. Ribeiro et al studied, the EF of FLX, NFLX, VNF,
SBT, alprenolol, MET, PHO and bisoprolol (BSP = from the final effluent of the secondary clarifier
of three WWTPs located in the North of Portugal, Figure 5 [39]. Regarding antidepressants, only
R-FLX was detected in two of the WWTPs, indicating a faster degradation of the S-enantiomer during
the biological degradation [39]. VNF enantiomers were found between 40.4 and 129 ng/L in the
three WWTPs studied, with similar EF, which varied between 0.54 and 0.55, proving that VNF found
was not racemic [39]. Concerning the β-blockers enantiomers, BSP and PHO were found in all three
WWTPs, while MET was only found in two, however all of them under the medium quantification
level (MQL) [39].
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Table 3. Analytical methods of separation of several chiral illicit drugs and pharmaceuticals in different environmental matrices.
Drugs MatrixApplication Method Stationary Phase LOD/MDL LOQ/MQL Concentration Range/EF Reference
AM
MA
MDMA
MDA
Ephedrine
Wastewater UPLC/ESI-MS/MS
Chiral-CBH (100 × 2 mm,
5 µm); Chiral-CBH guard
column (10 × 2 mm)
n.r.
AM: 5.1 ng/L 0.5–1000 ng/L; EF:0.52–0.84 (mean 0.64)
[17]
MA: 0.6 ng/L 0.05–1000 ng/L; EF ≥ 0.5
MDMA: 0.7 ng/L 0.1–1000 ng/L; EF = 0.68
MDA: 4.2 ng/L 0.1–1000 ng/L; EF > 0.5
Ephedrine: 5.6 ng/L 0.5–1000 ng/L; EF:0.81–0.96 (mean 0.91)
AM, MA, MDMA,
MDA, Ephedrine,
Pseudoephedrine,
Norephedrine,
Atenolol,
Alprenolol, PHO,
MET, T, SBT,
Sotalol, FLX,
Mirtazapine,
VNF, OD-VNF,
Citalopram,
D-citalopram
Influent
wastewater
(IW); effluent
wastewater
(EW); digested
sludge (DS)
LC/ESI-MS/MS
Chiral-CBH (100 × 2 mm,
5 µm); Chiral-CBH guard
column (10 × 2 mm)
AM (R/S): 0.38/0.39 ng/L (IW); 0.28/0.41
ng/L (EW); 4.92/5.15 ng/L (DS)
AM (R/S): 1.28/1.32 ng/L (IW); 0.94/1.36
ng/L (EW); 16.56/17.28 ng/L (DS)
0.025–250 µg/L;
EF: 0.5 (IW); 0.6 (EW); 0.3
(DS)
[62]
MA (R/S): 0.12/0.13 ng/L (IW); 0.09/0.08
ng/L (EW); 0.73/0.77 ng/L (DS)
MA (R/S): 0.38/0.41 ng/L (IW); 0.28/0.27
ng/L (EW); 3.24/2.45 ng/L (DS)
0.025–250 µg/L
EF: 0.6 (IW); 0.5 (EW); 0.5
(DS)
MDMA: 0.05 ng/L (IW); 0.04 ng/L (EW);
1.43/1.79 ng/L (R/S) (DS)
MDMA (R/S): 0.17/0.18 ng/L (IW);
0.13/0.14 ng/L (EW); 4.75/5.96 ng/L (DS)
0.025–250 µg/L
EF: 0.7 (IW); 0.9 (EW); 0.4
(DS)
MDA (R/S): 0.33/0.36 ng/L (IW); 0.21/0.25
ng/L (EW); 2.21/4.14 ng/L (DS)
MDA (R/S): 1.13/1.19 ng/L (IW); 0.72/0.83
ng/L (EW); 7.46/13.74 ng/L (DS)
0.025–250 µg/L
EF: 0.6 (IW); 0.5 (EW); 0.3
(DS)
Ephedrine (1R,2S/1S,2R): 0.23/0.16 ng/L
(IW); 0.14/0.07 ng/L (EW)
Ephedrine (1R,2S/1S,2R): 0.01/0.02 ng/L
(IW); 0.48/0.25 ng/L (EW)
0.025–250 µg/L
EF: 0 (IW, EW)
Pseudoephedrine (1R,2R/1S,2S): 0.26/0.1
ng/L (IW); 0.15/0.11 ng/L (EW);
15.54/44.53 ng/L (DS)
Pseudoephedrine (1R,2R/1S,2S): 0.01/0.03
ng/L (IW); 0.52/0.36 ng/L (EW);
51.62/148.5 ng/L (DS)
0.025–250 µg/L
EF: 1 (IW); 0.2 (EW)
Norephedrine (E1/E2): 0.33/0.15 ng/L (IW);
0.19/0.21 ng/L (EW); 9.54/13.05 ng/L (DS)
Norephedrine (E1/E2): 0.01/0.02 ng/L (IW);
0.63/0.71 ng/L (EW); 31.52/43.38 ng/L (DS)
0.025–250 µg/L
EF: 0 (IW); 0.3 (EW); 0.1
(DS)
Chirobiotic V
(250 × 2.1 mm, 5 µm)
Atenolol (R/S): 28.74/17.40 ng/L (IW);
30.80/32.73 ng/L (EW); 7.55/7.12 ng/L (DS)
Atenolol (R/S): 95.81/58 ng/L (IW);
102.68/109.08 ng/L (EW); 25.15/23.70 ng/L
(DS)
0.025–250 µg/L
EF: 0.5 (IW, EW); 0.4 (DS)
Alprenolol (R/S): 0.14/0.07 ng/L (IW);
0.06/0.03 ng/L (EW); 0.14 ng/L (DS)
Alprenolol (R/S): 0.47/0.24 ng/L (IW);
0.21/0.09 ng/L (EW); 0.48/0.46 ng/L (DS)
0.025–250 µg/L
EF: 0.5 (IW, EW); 0.7 (DS)
PHO (R/S): 0.08/0.09 ng/L (IW); 0.06/0.05
ng/L (EW); 0.07/0.06 ng/L (DS)
PHO (R/S): 0.26/0.3 ng/L (IW); 0.20/0.17
ng/L (EW); 0.23/0.20 ng/L (DS)
0.025–250 µg/L
EF: 0.4 (IW, EW); 0.5 (DS)
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Table 3. Cont.
Drugs MatrixApplication Method Stationary Phase LOD/MDL LOQ/MQL Concentration Range/EF Reference
MET (R/S): 0.08/0.06 ng/L (IW); 0.05/0.04
ng/L (EW); 0.05/0.07 ng/L (DS)
MET (R/S): 0.27/0.18 ng/L (IW); 0.15/0.12
ng/L (EW); 0.15/0.22 ng/L (DS)
0.025–250 µg/L
EF: 0.3 (IW, DS)
T (E1/E2): 0.09/0.43 ng/L (IW); 0.05/0.24
ng/L (EW); 0.05/0.34 ng/L (DS)
T (E1/E2): 0.29/1.43 ng/L (IW); 0.16/0.79
ng/L (EW); 0.18/1.13 ng/L (DS)
0.025–250 µg/L
EF: 0.7 (IW, EW, DS)
SBT (R/S): 2.22/2.20 ng/L (IW); 1.31/0.98
ng/L (EW); 80.03/65.03 ng/L (DS)
SBT (R/S): 7.41/7.32 ng/L (IW); 4.36/3.26
ng/L (EW); 265.10/225.10 ng/L (DS)
0.025–250 µg/L
EF: 0.5 (IW, EW)
Sotalol (E1/E2): 0.66/0.61 ng/L (IW);
0.53/0.46 ng/L (EW); 1.64/0.76 ng/L (DS)
Sotalol (E1/E2): 2.20/2.05 ng/L (IW);
1.76/1.53 ng/L (EW); 5.47/5.87 ng/L (DS)
0.025–250 µg/L
EF: 0.5 (IW, EW, DS)
FLX (R/S): 0.08/0.07 ng/L (IW); 0.05/0.04
ng/L (EW); 0.09/0.07 ng/L (DS)
FLX (R/S): 0.26/0.22 ng/L (IW); 0.17/0.14
ng/L (EW); 0.30/0.23 ng/L (DS)
0.025–250 µg/L
EF: 0.7 (IW, EW, DS)
Mirtazapine (R/S): 0.40/1.17 ng/L (IW);
0.40/0.86 ng/L (EW); 0.31/0.73 ng/L (DS)
Mirtazapine (R/S): 1.32/3.89 ng/L (IW);
1.32/2.86 ng/L (EW); 1.02/2.44 ng/L (DS)
0.025–250 µg/L
EF: 0.3 (IW); 0.2 (EW); 0.5
(DS)
VNF (R/S): 0.03/0.04 ng/L (IW); 0.02/0.03
ng/L (EW); 0.03 ng/L (DS)
VNF (R/S): 0.11/0.12 ng/L (IW); 0.07/0.11
ng/L (EW); 0.08 ng/L (DS)
0.025–250 µg/L
EF: 0.5 (IW, EW, DS)
OD-VNF (R/S): 0.32/0.16 ng/L (IW);
0.38/0.08 ng/L (EW); 0.75/1.02 ng/L (DS)
OD-VNF (R/S): 1.05/3.85 ng/L (IW);
1.28/2.30 ng/L (EW); 2.51/3.41 ng/L (DS)
0.025–250 µg/L
EF: 0.5 (IW, EW, DS)
Citalopram (R/S): 0.31/0.24 ng/L (IW);
0.27/0.21 ng/L (EW); 0.21/0.09 ng/L (DS)
Citalopram (R/S): 13.69/13.07 ng/L (IW);
11.78/11.15 ng/L (EW); 9.09/4.69 ng/L (DS)
0.025–250 µg/L
EF: 0.6 (IW, DS); 0.7 (EW)
D-Citalopram (R/S): 0.50/0.36 ng/L (IW);
0.40/0.29 ng/L (EW); 0.42/0.36 ng/L (DS)
D-Citalopram (R/S): 1.68/1.21 ng/L (IW);
1.34/0.96 ng/L (EW); 1.99/1.22 ng/L (DS)
0.025–250 µg/L
EF: 1 (IW); 0.6 (DS)
AM, MA,
MDMA,
MDA, MDEA,
Norephedrine,
VNF
WWTP
influent (IW);
WWTP
effluent (EW)
UPLC/ESI-MS/MS
Chiral-CBH (100 × 2 mm,
5 µm); Chiral-CBH guard
column (10 × 2 mm)
AM (R/S): 0.85/0. 9 ng/L (IW); 0.9/0.85
ng/L (EW)
AM (R/S): 4.35/4.4 ng/L (IW); 4.4/4.35
ng/L (EW)
0.25–1900 ng/L
EF n.r.
[149]
MA: 0.85/0. 9 ng/L (R/S) (IW); 1 ng/L (EW) MA: 2.8/2.95 ng/L (R/S) (IW); 3.35 ng/L(EW)
0.25–1900 ng/L
EF n.r.
MDMA: 0.9 ng/L (IW); 0.95/1 ng/L (E1/E2)
(EW)
MDMA: 2.4 ng/L (IW); 2.55–2.65 ng/L
(E1/E2) (EW)
0.25–1900 ng/L
EF: 0.53–0.72 (mean 0.63)
(IW); 0.71 (EW)
MDA: 1.95/2 ng/L (E1/E2) (IW); 2 ng/L
(EW) MDA: 9.7 ng/L (IW); 10.1 ng/L (EW)
0.25–1900 ng/L
EF n.r.
MDEA: 0.55 ng/L (IW); 0.6 ng/L (EW) MDEA: 2.25/2.2 ng/L (E1/E2) (IW); 2.4ng/L (EW)
0.25–1900 ng/L
EF n.r.
Norephedrine (E1/E2): 3.5/3.3 ng/L (IW);
1.4/1.35 ng/L (EW)
Norephedrine (E1/E2): 11.75/10.9 ng/L
(IW); 4.6/4.5 ng/L (EW)
0.25–1900 ng/L
EF n.r.
VNF: 1.6 ng/L (IW); 1.65 ng/L (EW) VNF: 4.95/5.05 ng/L (E1/E2) (IW); 5.1 ng/L(EW)
0.25–1900 ng/L
EF: 0.45–0.50 (mean 0.48)
(IW); 0.37–0.48 (mean 0.43)
(EW)
Molecules 2018, 23, 262 28 of 47
Table 3. Cont.
Drugs MatrixApplication Method Stationary Phase LOD/MDL LOQ/MQL Concentration Range/EF Reference
AM, MA,
MDMA,
MDA,
Ephedrine,
Atenolol, VNF
WWTP
influent (IW);
WWTP effluent
(EW); river
water (RW)
LC/ESI-MS/MS
Chiral-CBH (100 × 2 mm,
5 µm); Chiral-CBH guard
column (10 × 2 mm)
n.r. n.r.
AM: 1–500 ng/L
EF: 0.52–0.84 (mean 0.64) (IW); 0.57–1 (mean 0.78) (EW); 0.86
(RW before WWTP); 0.81 (RW after WWTP)
[9]
MA: 1–500 ng/L
EF: 0.22–0.53 (mean 0.34) (IW); 0.7–1 (mean 0.86) (EW)
MDMA: 1–500 ng/L
EF: 0.5–0.8 (mean 0.66) (IW); 0.64–0.91 (mean 0.75) (EW);
0.56–0.81 (mean 0.68) (RW before WWTP); 0.61–0.80 (mean
0.69) (RW after WWTP)
MDA: 1–500 ng/L
EF: 0.26–0.47 (mean 0.34) (IW); 0.38–0.58 (mean 0.45) (EW);
0.58 (RW before WWTP); 0.56–0.57 (RW after WWTP)
Ephedrine: 1–500 ng/L
EF: 0.81–1 (mean 0.99) (IW); 0.22–1 (mean 0.92) (EW); 0.79–1
(mean 0.97) (RW before WWTP); 0.80–1 (mean 0.99) (RW after
WWTP)
DF: 0.02–0.66 (mean 0.26) (IW); 0.04–0.82 (mean 0.36) (EW);
0–1 (mean 0.6) (RW before WWTP); 0–1 (mean 0.46) (RW after
WWTP)
VNF: 1–500 ng/L
EF: 0.35–0.65 (mean 0.48) (IW); 0.46–0.69 (mean 0.52) (EW);
0.40–0.65 (mean 0.52) (RW before WWTP); 0.47–0.62 (mean
0.51) (RW after WWTP)
Atenolol: 1.7 ng/L (IW,
EW); 0.3 ng/L (RW)
1–500 ng/L
EF: 0.30–0.47 (mean 0.40) (IW); 0.40–0.61 (mean 0.46) (EW);
0.38–0.56 (mean 0.46) (RW before WWTP); 0.39–0.50 (mean
0.45) (RW after WWTP)
AM, MA, MDMA,
MDA, Atenolol,
PHO, MET, FLX,
VNF
Sewage
effluent (SE);
River water
(RW)
LC/QTOF-MS
Chirobiotic V (250 × 4.6
mm, 5 µm); Chirobiotic V
guard column (20 × 40
mm, 5 µm)
AM: 4.6/4.4 ng/L (R/S)
(SE); 1.8 ng/L (RW)
AM (R/S): 12.4/11.5
ng/L (SE); 5.0/4.8 ng/L
(RW)
0.5–500 ng/L
EF n.r.
[151]
MA (R/S): 11.9/14.2
ng/L (SE); 4.6/5.5 ng/L
(RW)
MA (R/S): 47.6/47.3
ng/L (SE); 18.5/18.3
ng/L (RW)
0.25–500 ng/L
EF n.r.
MDMA (E1/E2):
22.8/21.8 ng/L (SE);
9.6/10.4 ng/L (RW)
MDMA (E1/E2):
85.7/81.9 ng/L (SE);
35.8/39 ng/L (RW)
5–500 ng/L
EF n.r.
Atenolol (R/S): 5/5.3
ng/L (SE); 2.1/2.2 ng/L
(RW)
Atenolol (R/S): 11.4/11
ng/L (SE); 4.8/4.7 ng/L
(RW)
0.25–100/5–500 ng/L (R); 0.5–100/5–500 ng/L (S)
EF: 0.55 (SE); 0.47 (RW)
PHO (R/S): 1.4/1 ng/L
(SE); 0.6/0.4 ng/L (RW)
PHO (R/S): 3.4/2.6
ng/L (SE); 1.4/1.2 ng/L
(RW)
0.25–100/5–500 ng/L
EF: 0.43 (SE); 0.45 (RW)
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Drugs MatrixApplication Method Stationary Phase LOD/MDL LOQ/MQL Concentration Range/EF Reference
MET: 0.6/0.7 ng/L (E1/E2) (SE); 0.2 ng/L
(RW)
MET: 1.3 ng/L (SE); 0.3/0.4 ng/L
(E1/E2) (RW)
0.25–100/5–500 ng/L
EF: 0.54 (SE)
FLX: 2.4/2.6 ng/L (R/S) (SE); 0.8 ng/L
(RW)
FLX (R/S): 7.6/6.5 ng/L (SE); 2.5/2
ng/L (RW)
0.25–100/5–500 ng/L
EF n.r.
VNF (R/S): 4.8/3.9 ng/L (SE); 2.5/2.2
ng/L (RW)
VNF (R/S): 15.1/14.4 ng/L (SE);
7.9/8.1 ng/L (RW)
0.5–100/5–500 ng/L
EF: 0.43 (SE); 0.58 (RW)
Chiral-CBH (100 × 2 mm,
5 µm); Chiral-CBH guard
column (10 × 2 mm, 5 µm)
AM (R/S): 4.8/5 ng/L (RW) AM (R/S): 9.7/10 ng/L (RW) 0.5–500 ng/LEF n.r.
MA (R/S): 4.1/3.6 ng/L (RW) AM (R/S): 20.6/18.1 ng/L (RW) 2.5–500 ng/LEF n.r.
MDMA (R/S): 10.7/10.2 ng/L (RW) MDMA (R/S): 26.8/25.6 ng/L(RW)
12.5–500 ng/L
EF n.r.
MDA (R/S): 2.4/2.3 ng/L (RW) MDA (R/S): 9.6/9.1 ng/L (RW) 1.75–500 ng/LEF n.r.
Atenolol (R/S): 2.3/2.1 ng/L (RW) Atenolol (R/S): 22.9/20.7 ng/L(RW)
0.5–500 ng/L
EF n.r.
VNF (E1/E2): 10.3/9.6 ng/L (RW) VNF (E1/E2): 51.7/47.9 ng/L (RW) 5–500 ng/LEF n.r.
Atenolol, PHO,
MET, SBT,
Sotalol, Nadolol,
Pindolol, FLX,
Citalopram
Influent
wastewater
(IW); Effluent
wastewater
(EW)
LC/ESI-MS/MS
Chirobiotic V (250 × 4.6 mm,
5 µm) with a nitrile guard
cartridge (10 × 3 mm)
Atenolol: 1.8 ng/L (IW); 1.4 ng/L (EW) 6 ng/L (IW); 5 ng/L (EW)
1–500 ng/mL
EF n.r.
[152]
PHO: 0.5 ng/L (IW, EW) 2 ng/L (IW, EW)
MET: 2.3 ng/L (IW); 0.6 ng/L (EW) 8 ng/L (IW); 2 ng/L (EW)
SBT: 0.7 ng/L (IW); 0.6 ng/L (EW) 2 ng/L (IW, EW)
Sotalol: 7.5 ng/L (IW); 7.2 ng/L (EW) 25 ng/L (IW); 24 ng/L (EW)
Nadolol: 1.8 ng/L (IW); 1.7 ng/L (EW) 12 ng/L (IW); 3 ng/L (EW)
Pindolol: 0.4 ng/L (IW); 0.2 ng/L (EW) 1 ng/L (IW, EW)
FLX: 2.2 ng/L (IW); 0.6 ng/L (EW) 7 ng/L (IW); 2 ng/L (EW)
Citalopram: 2.4 ng/L (IW); 0.5 ng/L (EW) 8 ng/L (IW); 2 ng/L (EW)
Atenolol, PHO,
MET
WWTP
influent (IW);
WWTP
effluent (EW)
HPLC/ESI-MS/MS
Chirobiotic V (250 × 4.6 mm,
5 µm) with a nitrile guard
cartridge (10 × 3 mm) and an
in-line filter
Atenolol: 110 ng/L IW); 12 ng/L (EW) n.r. 25–1000 ng/mLEF ≈ 0.5 (IW; EW)
[153]PHO: 17 ng/L (IW); 4.4 ng/L (EW) n.r. 25–1000 ng/mLEF ≈ 0.5 (IW; EW)
MET: 42 ng/L (IW); 17 ng/L (EW) n.r. 25–1000 ng/mLEF: 0.5 (IW); 6=0.5 (EW)
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Drugs MatrixApplication Method Stationary Phase LOD/MDL LOQ/MQL Concentration Range/EF Reference
Atenolol, MET,
Sotalol,
Citalopram,
Temazepam
Effluent
wastewater
LC/ESI-MS/MS
Chirobiotic V (250 × 4.6 mm,
5 µm)
n.r. n.r.
Atenolol EF: 0.40–0.52 (mean
0.46)
[142]
MET EF: 0.39–0.52 (mean
0.46)
Sotalol EF: 0.34–0.41 (mean
0.36)
Citalopram EF: 0.44–0.62
(mean 0.58)
Chiralpak AD-RH (150 × 4.6 mm,
5 µm) n.r. n.r.
Temazepam EF: 0.39–0.49
(mean 0.47)
Atenolol, PHO,
MET, Bisoprolol River water LC-UV
Lux Cellulose-1 (250 × 4.6 mm,
5 µm)
Atenolol: 22 µg/L 70 µg/L
12.5–100 µg/mL
EF n.r. [154]
PHO: 3 µg/L 10 µg/L
MET: 20 µg/L 40 µg/L
Bisoprolol: 3 µg/L 10 µg/L
Alprenolol, PHO,
MET, SBT,
Bisoprolol, FLX,
NFLX, VNF
WWTP effluent LC/ESI-MS/MS
Chirobiotic V (150 × 2.1 mm,
5 µm)
Alprenolol (R/S): 8.08/4.52 ng/L Alprenolol (R/S): 18.5/13.7 ng/L
20–400 ng/L
EF n.r.
[39]
PHO (R/S): 1.97/0.65 ng/L PHO (R/S): 5.96/1.98 ng/L
MET (R/S): 11.5/3.37 ng/L MET (R/S): 14.8/10.2 ng/L
SBT (R/S): 5.07/6.29 ng/L SBT (R/S): 15.4/19.1 ng/L
Bisoprolol (E1/E2): 2.78/4.54 ng/L Bisoprolol (E1/E2): 8.44/13.8 ng/L
FLX (R/S): 8.41/3.74 ng/L FLX (R/S):19.5/11.3 ng/L
NFLX (R/S): 0.97/5.27 ng/L NFLX (R/S): 2.95/16 ng/L 30–400 ng/LEF n.r.
VNF (R/S): 9.82/1.71 ng/L VNF (R/S): 19.7/5.18 ng/L 20–400 ng/LEF: 0.54–0.55 (mean 0.55)
Alprenolol, PHO,
MET, FLX, VNF,
Ibuprofen,
Naproxen,
Flurbiprofen
Surface water LC/ESI-MS/MS
Chirobiotic V (250 × 4.6 mm,
5 µm); Chirobiotic V guard
column (20 × 4 mm, 5 µm)
Alprenolol (R/S): 0.2/0.1 ng/L Alprenolol (R/S): 0.5/0.4 ng/L 5–1000 µg/LEF n.r.
[37]
PHO (R/S): 0.6/0.5 ng/L PHO (R/S): 2.1/1.7 ng/L 5–1000 µg/LEF: 0.44–0.56 (mean 0.49)
MET: 0.2 ng/L MET (R/S): 0.6/0.5 ng/L 5–1000 µg/LEF: 0.48–0.64 (mean 0.55)
FLX: 0.1 ng/L 0.5 ng/L 5–1000 µg/L; EF: 0.5–0.63
VNF: 0.1 ng/L 0.5 ng/L 5–1000 µg/L; EF: 0.46–0.51(mean 0.49)
Chiralpak AD-RH (150 × 4.6 mm,
5 µm)
Ibuprofen (R/S): 11/9.6 ng/L Ibuprofen (R/S): 37/32 ng/L
5–1000 µg/L
EF n.r.Naproxen: 0.4 ng/L Naproxen (R/S): 1.4/1.2 ng/L
Flurbiprofen (R/S): 3.3/2.4 ng/L Flurbiprofen (R/S): 11/7.9 ng/L
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Drugs MatrixApplication Method Stationary Phase LOD/MDL LOQ/MQL
Concentration
Range/EF Reference
PHO
Influent
wastewater (IW);
Effluent
wastewater (EW);
Surface water
(SW)
GC/ESI-MS/MS MDN-5S (30 m × 0.25 mm, 0.25 µm filmthickness) n.r. n.r.
EF: 0.5 (IW); ≤0.42
(EW); 0.42–0.53 (SW) [155]
PHO River water LC-UV Lux-Cellulose 1 (250 × 4.6 mm, 5 µm) 0.4 µg/L 1.3 µg/L 0.125–50 µg/mL; EF n.r. [156]
MET
Influent
wastewater (IW);
Effluent
wastewater (EW)
LC/ESI-MS/MS Chirobiotic V (250 × 4.6 mm, 5 µm) 3.7/3.5 ng/L (IW); 1.9/1.5 ng/L(EW) (R/S)
12.4/11.5 ng/L (IW); 6.5/5.1 ng/L
(EW) (R/S)
EF: 0.48–0.52 (IW);
0.5–0.7 (EW) [40]
MET Treatedwastewater LC/MS/MS
Chiral-CBH (100 × 2 mm, 5 µm);
Chiral-CBH guard column and in-line
high-pressure filter (4 mm, 0.5 µm)
0.96/2.9 pM (E1/E2) 5.8/11.6 pM (E1/E2) EF: 0.51–0.55 [157]
MET
Effluent
wastewater (EW);
River water (RW)
GC/ESI-MS/MS MDN-5S (30 m × 0.25 mm, 0.25 µm filmthickness) n.r. n.r.
EF: 0.5 (EW); 0.31–0.44
(RW) [158]
FLX, NFLX
Raw wastewater
(RaW); Treated
wastewater (TW)
LC/ESI-MS/MS
Chiral-AGP (100 × 2 mm, 5 µm); in-line
high-pressure filter with a replaceable
cap frit (4 mm, 5 µm); Chiral-AGP guard
column (10 × 2 mm)
FLX: 3 pM (RaW); 2/1 pM (R/S)
(TW) FLX: 12.4 pM (RaW); 3 pM (TW)
0–500 pM
EF: 0.71 (RaW, TW) [159,160]
NFLX: 2.4 pM (RaW); 2 pM (TW) NFLX: 12.1/14.3 pM (E1/E2)(RaW); 4 pM (TW)
0–500 pM
EF: 0.69 (RaW); 0.68
(TW)
FLX, NFLX WWTP effluent HPLC-FD Chirobiotic V (150 × 4.6 mm, 5 µm) FLX: 0.8–2 ng/mL 4 ng/mL 4–60 ng/mL; EF n.r. [137]
NFLX: 0.8–2 ng/mL 2 ng/mL 2–30 ng/mL; EF n.r.
VNF River water LC/ESI-MS/MS Chirobiotic V (250 × 2.1 mm, 5 µm);Chirobiotic guard column (10 × 2 mm) 6/4 ng/L (R/S) n.r. EF: 0.46–0.74 [144]
Ibuprofen,
Carboxyibuprofen,
2-Hydroxyibuprofen,
Naproxen,
Ketoprofen,
Indoprofen,
Chloramphenicol,
Ifosfamide,
Praziquantel
Influent
wastewater (IW);
Effluent
wastewater (EW);
Surface water (SW)
LC/ESI-MS/MS Chirobiotic T (250 × 2.1 mm, 5 µm)
Ibuprofen (R/S): 1319/1111 ng/L
(IW); 498/383 ng/L (EW);
263/114 ng/L (SW)
Ibuprofen (R/S): 5403/4551 ng/L
(IW); 2039/1570 ng/L (EW);
1076/466 ng/L (SW)
250–400 µg/L
EF: 1 (IW)
[161]
Carboxyibuprofen (E1/E2):
71/63.6 ng/L (IW); 71.4/58.6
ng/L (EW); 21.5/22.3 ng/L (SW)
Carboxyibuprofen (E1/E2):
232/208 ng/L (IW); 233/191 ng/L
(EW); 70.2/72.7 ng/L (SW)
32.7–300 µg/L (IW);
250–400 µg/L (EW, SW)
EF: 0.83 (IW)
2-Hydroxyibuprofen (E1/E2):
31.7/20.4 ng/L (IW); 28/30.4
ng/L (EW); 10.9/10.4 ng/L (SW)
2-Hydroxyibuprofen (E1/E2):
104/66.4 ng/L (IW); 91.3/99.3
ng/L (EW); 35.4/33.9 ng/L (SW)
16.3–400 µg/L (E1);
16.3–300 µg/L (E2)
EF: 0.76 (IW)
Naproxen (R/S): 11/7.53 ng/L
(IW); 14.4/13.4 ng/L (EW);
7.5/6.83 ng/L (SW)
Naproxen (R/S): 38.1/26.1 ng/L
(IW); 49.9/46.5 ng/L (EW);
25.9/23.7 ng/L (SW)
8.66–50 µg/L
EF: 1 (IW)
Ketoprofen (R/S): 2.08/2.61 ng/L
(IW); 2.28/2.56 ng/L (EW);
1.60/1.32 ng/L (SW)
Ketoprofen (R/S): 6.85/8.59 ng/L
(IW); 7.51/8.44 ng/L (EW);
5.29/4.37 ng/L (SW)
1.65–400 µg/L
EF n.r.
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Indoprofen (E1/E2): 2.23/3.44 ng/L
(IW); 2.20/2.59 ng/L (EW); 1.54/1.46
ng/L (SW)
Indoprofen (E1/E2): 7.59/11.7
ng/L (IW); 7.47/8.81 ng/L (EW);
5.24/4.95 ng/L (SW)
1.70–100 µg/L
EF n.r.
Chloramphenicol (1R,2R/1S,2S):
29.1/5.66 ng/L (IW); 26.1/4.84 ng/L
(EW); 13.5/2.59 ng/L (SW)
Chloramphenicol (1R,2R/1S,2S):
98.9/18.8 ng/L (IW); 88.6/16.1
ng/L (EW); 45.8/8.61 ng/L (SW)
17–400 µg/L (1R,2R);
3.33–800 µg/L (1S,2S)
EF n.r.
Ifosfamide (E1/E2): 0.24/0.28 ng/L
(IW); 0.23/0.22 ng/L (EW); 0.12/0.13
ng/L (SW)
Ifosfamide (E1/E2): 0.82/0.96 ng/L
(IW); 0.78/0.74 ng/L (EW);
0.41/0.44 ng/L (SW)
0.17–50 µg/L
EF n.r.
Praziquantel (E1/E2): 3.02/3.11 ng/L
(IW); 2.78/2.82 ng/L (EW); 1.34/1.39
ng/L (SW)
Praziquantel (E1/E2): 10.1/10.4
ng/L (IW); 9.26/9.40 ng/L (EW);
4.47/4.63 ng/L (SW)
1.67–400 µg/L
EF n.r.
Ibuprofen, Naproxen
Influent
wastewater (IW);
Effluent
wastewater (EW)
GC/MS
Astec Chiraldex (20 m ×
0.25 mm, 0.12 µm film
thickness)
0.1 µg/L n.r.
Ibuprofen EF: 0.73–0.90
(IW); 0.60–0.76 (EW)
[44]
Naproxen EF: 0.88–0.90
(IW); 0.71–0.86 (EW)
Ibuprofen, Naproxen,
Ketoprofen
Influent
wastewater (IW);
Effluent
wastewater (EW)
GC/EI-MS/MS HP5-MS (30 m × 0.25 mm,
0.25 µm film thickness)
n.r. n.r.
Ibuprofen EF: 0.88–0.94
(IW); 0.38–0.40 (EW)
[162]Naproxen EF: 0.99 (IW);
0.86–0.94 (EW)
Ketoprofen EF: 0.56–0.60
(IW); 0.54–0.68 (EW)
Ibuprofen,
2-Hydroxyibuprofen,
Naproxen, Indoprofen,
Carprofen, Fenoprofen,
Flurbiprofen,
Chloramphenicol,
Aminorex, Tetramisole,
Omeprazole, Ifosfamide,
3-N-Dechloroethylifosfamide,
Praziquantel, Imazalil,
Ofloxacin
Influent
wastewater (IW);
Effluent
wastewater (EW)
UHPSFC/ESI-MS/MS
Polysaccharide amylose
tris-(3,5-dimethylpheny
lcarbamate) column
Ibuprofen (R/S): 1410/1525 ng/L
(IW); 1458/1452 ng/L (EW)
Ibuprofen (R/S): 4695/5080 ng/L
(IW); 4854/4837 ng/L (EW)
415–2000 µg/L
EF: 1 (IW)
[163]
2-Hydroxyibuprofen (E1/E2):
409/415 ng/L (IW)
2-Hydroxyibuprofen (E1/E2):
1360/1382 ng/L (IW)
163.5–2000 µg/L
EF: 0.2 (IW)
Naproxen: 233/267 ng/L (R/S) (IW);
539 ng/L (R) (EW)
Naproxen: 777/891 ng/L (R/S)
(IW); 1796 ng/L (R) (EW)
84.3–2000 µg/L
EF: 1 (IW, EW)
Indoprofen (E1/E2): 2.38/2.68 ng/L
(IW); 2.88/2.65 ng/L (EW)
Indoprofen (E1/E2): 7.91/8.91
ng/L (IW); 9.60/8.84 ng/L (EW)
0.85–250 µg/L (E1);
0.85–500 µg/L (E2)
EF n.r.
Carprofen (E1/E2): 378/287 ng/L
(IW); 584/705 ng/L (EW)
Carprofen (E1/E2): 1259/956 ng/L
(IW); 1945/2347 ng/L (EW)
168–500 µg/L
EF n.r.
Fenoprofen (E1/E2): 571/538 ng/L
(IW); 499/489 ng/L (EW)
Fenoprofen (E1/E2): 1900/1793
ng/L (IW); 1660/1632 ng/L (EW)
171–4000 µg/L
EF n.r.
Flurbiprofen: 331 ng/L (IW); 252/378
ng/L (E1/E2) (EW)
Flurbiprofen (E1/E2): 838/1101
ng/L (IW); 838/1259 ng/L (EW)
83.8–2000 µg/L
EF n.r.
Chloramphenicol (1R,2R/1S,2S):
45.6/43.5 ng/L (IW); 53.4/50.1 ng/L
(EW)
Chloramphenicol (1R,2R/1S,2S):
152/145 ng/L (IW); 178/167 ng/L
(EW)
16.9–500 µg/L (1R,2R);
16.7–500 µg/L (1S,2S)
EF n.r.
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Aminorex (E1/E2): 1.82/2.57 ng/L
(IW); 2.16/3.02 ng/L (EW)
Aminorex (E1/E2): 6.05/8.56 ng/L
(IW); 7.20/10 ng/L (EW)
0.83–500 µg/L
EF n.r.
Tetramisole (R/S): 2.54/2.94 ng/L
(IW); 2.83/2.87 ng/L (EW)
Tetramisole (R/S): 8.46/9.79 ng/L
(IW); 9.43/9.54 ng/L (EW)
0.83–500 µg/L
EF n.r.
Omeprazole: 24.5 ng/L (IW, EW) 81.6 ng/L (IW, EW)
0.82–125 µg/L (E1); 0.82–250 µg/L
(E2)
EF n.r.
Ifosfamide (E1/E2): 0.51/0.58 ng/L
(IW); 0.51/0.54 ng/L (EW)
Ifosfamide (E1/E2): 1.70/1.93 ng/L
(IW); 1.69/1.78 ng/L (EW)
0.17–125 µg/L
EF n.r.
3-N-Dechloroethyl-ifosfamide
(E1/E2): 0.46/3.22 ng/L (IW);
1.35/8.62 ng/L (EW)
3-N-Dechloroethyl-ifosfamide
(E1/E2): 1.54/10.70 ng/L (IW);
4.50/28.70 ng/L (EW)
0.17–50 µg/L (E1); 0.83–125 µg/L
(E2)
EF n.r.
Praziquantel (E1/E2): 2.66/2.47 ng/L
(IW); 2.64/2.77 ng/L (EW)
Praziquantel (E1/E2): 8.86/8.23
ng/L (IW); 8.78/9.23 ng/L (EW)
0.83–50 µg/L
EF n.r.
Cellulose
tris-(3-chloro-4-methylpheny
lcarbamate) column
Indoprofen (E1/E2): 5.53/3.94 ng/L
(IW); 6.82/5.52 ng/L (EW)
Indoprofen (E1/E2): 18.4/13.1
ng/L (IW); 22.7/18.4 ng/L (EW)
1.69–500 µg/L (E1); 1.69–250 µg/L
(E2)
EF n.r.
Aminorex (E1/E2): 2.32/2.54 ng/L
(IW); 2.23/3.44 ng/L (EW)
Aminorex (E1/E2): 7.74/8.44 ng/L
(IW); 7.59/11.70 ng/L (EW)
0.83–500 µg/L
EF: 0.4 (IW)
Tetramisole (R/S): 2.72/3.08 ng/L
(IW); 3.16/2.60 ng/L (EW)
Tetramisole (R/S): 9.06/10.30 ng/L
(IW); 10.50/8.65 ng/L (EW)
0.83–250 µg/L (R); 0.83–500 µg/L (S)
EF: 0.6 (IW, EW)
Omeprazole: 49 ng/L (IW, EW) 163 ng/L (IW, EW) 1.63–500 µg/LEF n.r.
3-N-Dechloroethyl-ifosfamide
(E1/E2): 2.81/2.99 ng/L (IW);
7.69/8.68 ng/L (EW)
3-N-Dechloroethyl-ifosfamide
(E1/E2): 9.35/9.97 ng/L (IW);
25.60/28.90 ng/L (EW)
0.83–125 µg/L
EF: 0.4 (IW)
Praziquantel (E1/E2): 6.62/5.59 ng/L
(IW); 6.80/5.30 ng/L (EW)
Praziquantel (E1/E2): 22/18.60
ng/L (IW); 22.60/17.60 ng/L (EW)
1.67–500 µg/L (E1); 1.67–250 µg/L
(E2)
EF n.r.
Imazalil (E1/E2): 5.12/5.16 ng/L
(IW); 7.09/6.45 ng/L (EW)
Imazalil (E1/E2): 17/17.20 ng/L
(IW); 23.60/21.50 ng/L (EW)
1.74–500 µg/L (E1); 1.74–250 µg/L
(E2)
EF: 0 (IW)
Ofloxacin (E1/E2): 98.20/63.10 ng/L
(IW); 65.20/79 ng/L (EW)
Ofloxacin (E1/E2): 327/210 ng/L
(IW); 218/263 ng/L (EW)
16.4–500 µg/L (E1); 16.4–250 µg/L
(E2)
EF: 0 (IW)
Ibuprofen,
Naproxen,
Ketoprofen
Effluent
wastewater
GC/EI-MS/MS
HP5-MS (30 m × 0.25 mm,
0.25 µm film thickness)
Ibuprofen: 0.7 ng/L (S) n.r. 0.08–300 ng/L; EF: 0.49–0.62 (mean0.53)
[147]
Naproxen: 0.7 ng/L (S) n.r. 0.08–300 ng/L; EF: 0.66–0.86 (mean0.79)
Ketoprofen: 2.2 ng/L (S) n.r. 3–300 ng/L; EF: 0.54–0.66 (mean 0.60)
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Ibuprofen,
Naproxen
Influent
wastewater (IW);
Effluent
wastewater (EW)
GC/EI-MS/MS
HP5-MS (30 m × 0.25
mm, 0.25 µm film
thickness)
n.r. n.r.
Ibuprofen EF: 0.6–0.8 (IW); 0.5
(EW)
[164]Naproxen EF: 1 (IW); 0.7–0.9
(EW)
Ibuprofen,
Naproxen,
Ketoprofen
Influent
wastewater (IW);
Effluent
wastewater (EW)
LC/MS/MS
Sumichiral OA-2500
(250 × 4.6 mm, 5 µm);
Chirex 3005 guard
column (30 × 4.6 mm,
5 µm)
Ibuprofen: 0.7 ng/L (IW); 0.5 ng/L (EW) n.r.
0.4–4000 µg/L
EF: 0.79–0.86 (IW); 0.63–0.68
(EW)
[165]Naproxen: 1.2/1.1 ng/L (R/S) (IW); 1.1
ng/L (EW) n.r.
1.2–4000 µg/L
EF: 0.98–0.99 (IW); 0.93–0.96
(EW)
Ketoprofen (R/S): 0.9/0.8 ng/L (IW); 0.8/0.7
ng/L (EW) n.r.
1–4000 µg/L
EF: 0.54–0.68 (IW); 0.61–0.68
(EW)
Ibuprofen,
Naproxen,
Ketoprofen,
Chloramphenicol,
Aminorex,
Tetramisole,
Ifosfamide,
3-N-Dechloroethy
lifosfamide,
Fexofenadine,
10,11-Dihydro-10
-hydroxy-
carbamazepine,
Praziquantel
Effluent
wastewater (EW);
Surface water (SW)
LC/ESI-MS/MS Chiral-AGP (100 × 2
mm, 5 µm); Chiral-AGP
guard column (10 × 2
mm, 5 µm)
Ibuprofen (R/S): 16.45/23.15 ng/L (EW);
9.15/9.39 ng/L (SW)
Ibuprofen (R/S): 67.37/94.81 ng/L
(EW); 37.47/38.46 ng/L (SW)
41–492 µg/L
EF: 0.65 (EW)
[32]
Naproxen (R/S): 3.45/4.16 ng/L (EW);
2.45/3.39 ng/L (SW)
Naproxen (R/S): 11.96/14.39 ng/L
(EW); 8.49/11.73 ng/L (SW)
8.66–416 µg/L (R); 8.66–312
µg/L (S)
EF: 0.92 (EW)
Ketoprofen: 0.52 ng/L (EW); 0.26/0.27 ng/L
(R/S) (SW)
Ketoprofen (R/S): 1.73/1.70 ng/L
(EW); 0.86/0.88 ng/L (SW)
0.83–297 µg/L (R); 0.83–396
µg/L (S)
EF n.r.
Chloramphenicol (1R,2R/1S,2S): 2.18/2.43
ng/L (EW); 1.02/1.19 ng/L (SW)
Chloramphenicol (1R,2R/1S,2S):
7.39/8.09 ng/L (EW); 3.46/3.96 ng/L
(SW)
3.40–612 µg/L (1R,2R); 3.33–400
µg/L (1S,2S)
EF n.r.
Aminorex: 0.12 ng/L (EW); 0.06 ng/L (SW) 0.39 ng/L (EW); 0.20 ng/L (SW) 0.17–100 µg/LEF n.r.
Tetramisole (R/S): 1.04/0.93 ng/L (EW);
0.48/0.47 ng/L (SW)
Tetramisole (R/S): 3.42/3.08 ng/L
(EW); 1.58/1.56 ng/L (SW)
1.65–396 µg/L (R); 1.65–297
µg/L (S)
EF: 0.50 (EW)
Ifosfamide: 0.09/0.08 ng/L (E1/E2) (EW);
0.04 ng/L (SW)
Ifosfamide (E1/E2): 0.31/0.29 ng/L
(EW);
0.14/0.15 ng/L (SW)
0.17–51 µg/L
EF n.r.
3-N-Dechloroethy-lifosfamide (E1/E2):
3.33/2.94 ng/L (EW); 1.09 /1.14 ng/L (SW)
3-N-Dechloroethy-lifosfamide
(E1/E2): 11.10/9.79 ng/L (EW);
3.62/3.78 ng/L (SW)
0.08–40 µg/L
EF n.r.
Fexofenadine (E1/E2): 56.02/58.10 ng/L
(EW); 33/34.66 ng/L (SW)
Fexofenadine (E1/E2): 190.29/197.33
ng/L (EW); 112.10/117.73 ng/L (SW)
136–306 µg/L (E1); 136–408
µg/L (E2)
EF: 0.55 (EW)
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10,11-Dihydro-10-hydroxy-carbama-zepine
(E1/E2): 1.08/1.06 ng/L (EW); 0.53/0.54
ng/L (SW)
10,11-Dihydro-10-hydroxy-carbama-zepine
(E1/E2): 3.58/3.53 ng/L (EW);
1.75/1.79 ng/L (SW)
1.67–100 µg/L (E1);
1.67–300 µg/L (E2)
EF n.r.
Praziquantel (E1/E2): 4.54/4.83 ng/L
(EW); 2.52/2.21 ng/L (SW)
Praziquantel (E1/E2): 15.12/16.07
ng/L (EW); 8.38/7.37 ng/L (SW)
8.33–400 µg/L (E1);
8.33–200 µg/L (E2)
EF n.r.
Naproxen
Influent
wastewater (IW);
Effluent
wastewater (EW);
River water (RW)
LC/ESI-MS/MS Chiralpak AD-RH (150 × 4.6mm) n.r. n.r.
EF: 1 (IW); 0.88–0.91
(EW); 0.84–0.98 (RW) [41]
Omeprazole,
Lansoprazole,
Rabeprazole,
Pantoprazole
Influent
wastewater (IW);
Effluent
wastewater (EW);
River water (RW)
LC/ESI-MS/MS Chiralpak IC (250 × 4.6 mm,
5 µm)
Omeprazole: 2.03/2.29 ng/L (R/S) (IW);
0.74 ng/L (EW); 0.67/0.68 ng/L (R/S)
(RW)
Omeprazole: 2.03/2.29 ng/L (R/S)
(IW); 2.81 ng/L (EW); 2.55/2.59 ng/L
(R/S) (RW)
2–500 µg/L
EF: 0.70 (IW); 0.53 (EW);
0.54 (RW)
[43]
Lansoprazole: 0.96/1.02 ng/L (R/S)
(IW); 0.69/0.70 ng/L (R/S) (EW); 0.67
ng/L (RW)
Lansoprazole (R/S): 4.34/4.63 ng/L
(IW); 3.13/3.20 ng/L (EW); 3.05/3.06
ng/L (RW)
2–500 µg/L
EF: 0.51 (IW); 0.52 (EW,
RW)
Rabeprazole: 0.94/0.95 ng/L (R/S) (IW);
0.71/0.73 ng/L (R/S) (EW); 0.78 ng/L
(RW)
Rabeprazole (R/S): 3.37/3.40 ng/L
(IW); 2.54/2.62 ng/L (EW); 2.81/2.78
ng/L (RW)
2–500 µg/L
EF: 0.52 (IW); 0.51 (RW)
Pantoprazole (E1/E2): 0.96/0.94 ng/L
(IW); 0.93/1 ng/L (EW); 0.96/0.91 ng/L
(RW)
Pantoprazole (E1/E2): 2.99/2.94 ng/L
(IW); 2.90/3.12 ng/L (EW); 2.99/2.83
ng/L (RW)
2–500 µg/L
EF: 0.54 (IW); 0.51 (EW);
0.53 (RW)
Econazole,
Miconazole,
Tebuconazole,
Ketoconazole
Raw wastewater
(RaW); Treated
wastewater (TW);
Sludge (Sd)
LC/ESI-MS/MS
AGP column (100 × 4 mm, 5 µm);
AGP guard column (10 × 4 mm)
n.r.
Econazole: 0.5 ng/L (RaW); 0.3 ng/L
(TW); 3 ng/g (Sd)
0.5–250 ng/mL
EF: 0.50 (Sd)
[166]
Miconazole: 0.5 ng/L (RaW); 0.3 ng/L
(TW); 3 ng/g (Sd)
0.5–250 ng/mL
EF: 0.5 (RaW); 0.47 (TW);
0.5 (Sd)
Tebuconazole: 0.8 ng/L/0.9 ng/L
(E1/E2) (RaW); 0.3 ng/L (TW); 4/5
ng/g (E1/E2) (Sd)
0.5–250 ng/mL
EF n.r.
HSA column (100 × 2 mm, 5 µm);
HSA guard column (10 × 2 mm) n.r.
Ketoconazole: 10 ng/L (RaW); 5 ng/L
(TW); 29 ng/g (Sd)
5–250 ng/mL
EF: 0.48 (RaW, TW, Sd)
Molecules 2018, 23, 262 36 of 47
Table 3. Cont.
Drugs MatrixApplication Method Stationary Phase LOD/MDL LOQ/MQL
Concentration
Range/EF Reference
Econazole,
Miconazole,
Tebuconazole,
Ketoconazole
River water (RW);
Sludge (Sd)
LC/ESI-MS/MS
AGP column (100 × 4 mm, 5 µm);
AGP guard column (10 × 4 mm)
n.r.
Econazole: 0.5 ng/L (RW); 3 ng/g (Sd) 0.5–250 ng/mL (Sd)EF: 0.52 (RW); 0.50 (Sd)
[167]
Miconazole: 0.6 ng/L (RW); 3ng/g (Sd)
0.5–250 ng/mL (Sd)
EF: 0.49–0.54 (RW);
0.50–0.52 (Sd)
Tebuconazole: 0.6 ng/L (RW) EF: 0.47–0.61 (RW)
HSA column (100 × 2 mm, 5 µm);
HSA guard column (10 × 2 mm) n.r.
Ketoconazole: 7 ng/L (RW); 29 ng/g
(Sd)
5–250 ng/mL (Sd)
EF: 0.48–0.49 (Sd)
Tebuconazole,
Hexaconazole,
Penconazole,
Triadimefon
River water LC/ESI-MS/MS
Chiralpak IC (250 × 4.6 mm,
5 µm)
Tebuconazole: 19.8 µg/L (−); 25.4 µg/L
(+) 60 µg/L (−); 76.2 µg/L (+)
30–1500 µg/L
EF n.r.
[168]
Hexaconazole: 9.1 µg/L (−); 8.6 µg/L
(+) 27.7 µg/L (−); 25.8 µg/L (+)
Penconazole: 29 µg/L (−); 27.6 µg/L (+) 88.1 µg/L (−); 83.8 µg/L (+)
Triadimefon: 8.5 µg/L 25.5 µg/L
AM: amphetamine; D-citalopram: desmethyl-citalopram; EF: enantiomeric fraction; ESI: electrospray ionization; FD: fluorescence detector; FLX: fluoxetin; GC: gas chromatography;
HPLC: high performance liquid chromatography; LC: liquid chromatography; LOD: limit of detection; LOQ: limit of quantification; MA: methamphetamine; MDA:
3,4-methylenedioxyamphetamine; MDL: method detection limit; MDMA: 3,4 methylenedioxymethamphetamine; MDEA: N-methyl-diethanolamine; MET: metoprolol; MS: mass
spectrometry; MS/MS: tandem mass spectrometry; MQL: method quantification limit; NFLX: norfluoxetin; PHO: propranolol; QTOF: quadrupole time of flight mass spectrometer;
OD-VNF: O-desmethylvenlafaxine; SBT: salbutamol; T: tramadol; UHPSFC: ultra high performance supercritical fluid chromatography; UPLC: ultra performance liquid chromatography;
UV: ultraviolet detector; VNF: venlafaxine. n.r.: not referred.
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5. General Conclusions and Further Perspectives
The LC-MS/MS is the first choice for environmental and biological matrices analyses due to the
low quantification limits, the selectivity and unequivocal identification. Regarding environmental
analysis the direct method by LC using CSP are mostly described. However methods for a complex
mixture of chiral drugs are still scarce. Chiral analyses in biological matrices describe many indirect
methods by GC, but the trend is the direct method by LC.
Despite the importance of the chiral analysis in forensic chemistry, this type of data are not
yet currently in used in certificated laboratories for doping control, criminal offense, environmental
monitoring and chiral drug control in general. In this sense more research is needed regarding new
enantioselectivity methods with different CSP and demonstrations with practical applications to
establish the importance of the chiral analysis in forensic chemistry.
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